<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Microbiol.</journal-id>
<journal-title>Frontiers in Microbiology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Microbiol.</abbrev-journal-title>
<issn pub-type="epub">1664-302X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmicb.2023.1189786</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Microbiology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Target specific inhibition of West Nile virus envelope glycoprotein and methyltransferase using phytocompounds: an <italic>in silico</italic> strategy leveraging molecular docking and dynamics simulation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Akash</surname>
<given-names>Shopnil</given-names>
</name>
<xref rid="aff1" ref-type="aff"><sup>1</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1833092/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bay&#x0131;l</surname>
<given-names>Imren</given-names>
</name>
<xref rid="aff2" ref-type="aff"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2221157/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rahman</surname>
<given-names>Md. Anisur</given-names>
</name>
<xref rid="aff3" ref-type="aff"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" equal-contrib="no">
<name>
<surname>Mukerjee</surname>
<given-names>Nobendu</given-names>
</name>
<xref rid="aff4" ref-type="aff"><sup>4</sup></xref>
<xref rid="aff5" ref-type="aff"><sup>5</sup></xref>
<xref rid="fn0003" ref-type="author-notes"><sup>&#x2020;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1417914/overview"/>
</contrib>
<contrib contrib-type="author" equal-contrib="no">
<name>
<surname>Maitra</surname>
<given-names>Swastika</given-names>
</name>
<xref rid="aff6" ref-type="aff"><sup>6</sup></xref>
<xref rid="fn0003" ref-type="author-notes"><sup>&#x2020;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2245502/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Islam</surname>
<given-names>Md. Rezaul</given-names>
</name>
<xref rid="aff1" ref-type="aff"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rajkhowa</surname>
<given-names>Sanchaita</given-names>
</name>
<xref rid="aff7" ref-type="aff"><sup>7</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1147150/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ghosh</surname>
<given-names>Arabinda</given-names>
</name>
<xref rid="aff8" ref-type="aff"><sup>8</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1142747/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Al-Hussain</surname>
<given-names>Sami A.</given-names>
</name>
<xref rid="aff9" ref-type="aff"><sup>9</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Zaki</surname>
<given-names>Magdi E. A.</given-names>
</name>
<xref rid="aff9" ref-type="aff"><sup>9</sup></xref>
<xref rid="c002" ref-type="corresp"><sup>&#x002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1684398/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jaiswal</surname>
<given-names>Vikash</given-names>
</name>
<xref rid="aff10" ref-type="aff"><sup>10</sup></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sah</surname>
<given-names>Sanjit</given-names>
</name>
<xref rid="aff11" ref-type="aff"><sup>11</sup></xref>
<xref rid="aff12" ref-type="aff"><sup>12</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Barboza</surname>
<given-names>Joshuan J.</given-names>
</name>
<xref rid="aff13" ref-type="aff"><sup>13</sup></xref>
<xref rid="c001" ref-type="corresp"><sup>&#x002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2216841/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sah</surname>
<given-names>Ranjit</given-names>
</name>
<xref rid="aff14" ref-type="aff"><sup>14</sup></xref>
<xref rid="aff15" ref-type="aff"><sup>15</sup></xref>
<xref rid="aff16" ref-type="aff"><sup>16</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/923326/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University</institution>, <addr-line>Dhaka</addr-line>, <country>Bangladesh</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Bioinformatics and Computational Biology, Gaziantep University</institution>, <addr-line>Gaziantep</addr-line>, <country>T&#x00FC;rkiye</country></aff>
<aff id="aff3"><sup>3</sup><institution>Department of Pharmacy, Islamic University</institution>, <addr-line>Kushtia</addr-line>, <country>Bangladesh</country></aff>
<aff id="aff4"><sup>4</sup><institution>Department of Microbiology, West Bengal State University</institution>, <addr-line>Kolkata, West Bengal</addr-line>, <country>India</country></aff>
<aff id="aff5"><sup>5</sup><institution>Department of Health Sciences, Novel Global Community Educational Foundation</institution>, <addr-line>Hebersham, NSW</addr-line>, <country>Australia</country></aff>
<aff id="aff6"><sup>6</sup><institution>Department of Microbiology, Adamas University</institution>, <addr-line>Kolkata, West Bengal</addr-line>, <country>India</country></aff>
<aff id="aff7"><sup>7</sup><institution>Centre for Biotechnology and Bioinformatics, Dibrugarh University</institution>, <addr-line>Dibrugarh, Assam</addr-line>, <country>India</country></aff>
<aff id="aff8"><sup>8</sup><institution>Microbiology Division, Department of Botany, Gauhati University</institution>, <addr-line>Gwahati, Assam</addr-line>, <country>India</country></aff>
<aff id="aff9"><sup>9</sup><institution>Department of Chemistry, Imam Mohammad Ibn Saud Islamic University (IMSIU)</institution>, <addr-line>Riyadh</addr-line>, <country>Saudi Arabia</country></aff>
<aff id="aff10"><sup>10</sup><institution>Department of Cardiovascular Research, Larkin Community Hospital</institution>, <addr-line>South Miami, FL</addr-line>, <country>United States</country></aff>
<aff id="aff11"><sup>11</sup><institution>Global Consortium for Public Health and Research, Datta Meghe Institute of Higher Education and Research, Jawaharlal Nehru Medical College</institution>, <addr-line>Wardha</addr-line>, <country>India</country></aff>
<aff id="aff12"><sup>12</sup><institution>SR Sanjeevani Hospital</institution>, <addr-line>Kayanpur, Siraha</addr-line>, <country>Nepal</country></aff>
<aff id="aff13"><sup>13</sup><institution>Escuela de Medicina, Universidad Cesar Vallejo</institution>, <addr-line>Trujillo</addr-line>, <country>Peru</country></aff>
<aff id="aff14"><sup>14</sup><institution>Tribhuvan University Teaching Hospital, Institute of Medicine</institution>, <addr-line>Kathmandu</addr-line>, <country>Nepal</country></aff>
<aff id="aff15"><sup>15</sup><institution>Dr. D. Y. Patil Medical College, Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeth, Pune</institution>, <addr-line>Maharashtra</addr-line>, <country>India</country></aff>
<aff id="aff16"><sup>16</sup><institution>Department of Public Health Dentistry, Dr. D.Y. Patil Dental College and Hospital, Dr. D.Y. Patil Vidyapeeth, Pune</institution>, <addr-line>Maharashtra</addr-line>, <country>India</country></aff>
<author-notes>
<fn id="fn0001" fn-type="edited-by"><p>Edited by: Arli Aditya Parikesit, Indonesia International Institute for Life-Sciences (i3L), Indonesia</p></fn>
<fn id="fn0002" fn-type="edited-by"><p>Reviewed by: Yong Guo, Zhengzhou University, China; Arif Nur Muhammad Ansori, Airlangga University, Indonesia</p></fn>
<corresp id="c001">&#x002A;Correspondence: Joshuan J. Barboza, <email>jbarbozame@ucvvirtual.edu.pe</email></corresp>
<corresp id="c002">Magdi E. A. Zaki, <email>mezaki@imamu.edu.sa</email></corresp>
<fn id="fn0003" fn-type="equal"><p><sup>&#x2020;</sup>These authors have contributed equally to this work</p></fn>
</author-notes>
<pub-date pub-type="epub">
<day>28</day>
<month>06</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>14</volume>
<elocation-id>1189786</elocation-id>
<history>
<date date-type="received">
<day>03</day>
<month>04</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>30</day>
<month>05</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2023 Akash, Bay&#x0131;l, Rahman, Mukerjee, Maitra, Islam, Rajkhowa, Ghosh, Al-Hussain, Zaki, Jaiswal, Sah, Barboza and Sah.</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Akash, Bay&#x0131;l, Rahman, Mukerjee, Maitra, Islam, Rajkhowa, Ghosh, Al-Hussain, Zaki, Jaiswal, Sah, Barboza and Sah</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Mosquitoes are the primary vector for West Nile virus, a flavivirus. The virus&#x2019;s ability to infiltrate and establish itself in increasing numbers of nations has made it a persistent threat to public health worldwide. Despite the widespread occurrence of this potentially fatal disease, no effective treatment options are currently on the market. As a result, there is an immediate need for the research and development of novel pharmaceuticals. To begin, molecular docking was performed on two possible West Nile virus target proteins using a panel of twelve natural chemicals, including Apigenin, Resveratrol, Hesperetin, Fungisterol, Lucidone, Ganoderic acid, Curcumin, Kaempferol, Cholic acid, Chlorogenic acid, Pinocembrin, and Sanguinarine. West Nile virus methyltransferase (PDB ID: 2OY0) binding affinities varied from &#x2212;7.4 to &#x2212;8.3&#x2009;kcal/mol, whereas West Nile virus envelope glycoprotein affinities ranged from &#x2212;6.2 to &#x2212;8.1&#x2009;kcal/mol (PDB ID: 2I69). Second, substances with larger molecular weights are less likely to be unhappy with the Lipinski rule. Hence, additional research was carried out without regard to molecular weight. In addition, compounds 01, 02, 03, 05, 06, 07, 08, 09, 10 and 11 are more soluble in water than compound 04 is. Besides, based on maximum binding affinity, best three compounds (Apigenin, Curcumin, and Ganoderic Acid) has been carried out molecular dynamic simulation (MDs) at 100&#x2009;ns to determine their stability. The MDs data is also reported that these mentioned molecules are highly stable. Finally, advanced principal component analysis (PCA), dynamics cross-correlation matrices (DCCM) analysis, binding free energy and dynamic cross correlation matrix (DCCM) theoretical study is also included to established mentioned phytochemical as a potential drug candidate. Research has indicated that the aforementioned natural substances may be an effective tool in the battle against the dangerous West Nile virus. This study aims to locate a bioactive natural component that might be used as a pharmaceutical.</p>
</abstract>
<kwd-group>
<kwd>West Nile virus</kwd>
<kwd>molecular docking</kwd>
<kwd>molecular dynamic simulation</kwd>
<kwd>PCA</kwd>
<kwd>drug-likeness</kwd>
<kwd>ADMET</kwd>
</kwd-group>
<counts>
<fig-count count="13"/>
<table-count count="6"/>
<equation-count count="1"/>
<ref-count count="78"/>
<page-count count="20"/>
<word-count count="12114"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Virology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="sec1" sec-type="intro">
<label>1.</label>
<title>Introduction</title>
<p>The infectious disease has the potential to cause a global pandemic and has been transmitted regularly throughout human history, such as plague, cholera, the flu, SARS-CoV, and MERS-CoV (<xref ref-type="bibr" rid="ref18">Fahmi et al., 2021</xref>; <xref ref-type="bibr" rid="ref45">Piret and Boivin, 2021</xref>). Besides, many infectious diseases may lead to pandemics, including Monkeypox, and Marburg virus (<xref ref-type="bibr" rid="ref19">Farahat and Memish, 2022</xref>). These infections were introduced to humans due to increased interaction with animals due to activities such as breeding, hunting, and global commerce. Recently, another new viral disease has been affecting people all over the globe, whose name is the West Nile virus. In 1937, researchers discovered the West Nile virus for the first time on the African continent, specifically in the West Nile area of Uganda (<xref ref-type="bibr" rid="ref55">Sule et al., 2018</xref>). Before 1997, the West Nile virus was not thought to be harmful to birds. However, in Israel around that time, a more dangerous strain of the virus was responsible for the deaths of many bird species with symptoms of encephalitis and paralysis. Since the beginning of the 1950s, several nations worldwide have reported cases of human infections caused by the West Nile virus (<xref ref-type="bibr" rid="ref25">Hayes, 2001</xref>). Today, the West Nile virus is the most common infectious disease spread by mosquitoes on the American continent. It is transmitted from person to person, most often by the bite of an infected mosquito. The West Nile virus infection was reported in two persons in New York City on August 16, 2022, one in Brooklyn and another in Queens. According to an announcement made by the New York City Health Department, the virus was also identified in a &#x201C;record number&#x201D; of infected mosquitoes around the city. According to the declaration made by the health authority, there have been a minimum of 54 instances detected throughout the continent this year, along with four fatalities. The risk of contracting the West Nile virus is highest during the mosquito season, which begins in the summer and lasts into the autumn (<xref ref-type="bibr" rid="ref41">New York Times, 2022</xref>).</p>
<p>The majority of people who have been diagnosed with the West Nile virus do not experience any symptoms of illness. Fever and other symptoms like headaches, body aches, joint pains, diarrhea, vomiting, or a rash arise in around one of every five infected patients. About one in every 150 infected persons may get a severe disease, which can often be deadly. Over the age of 60, people have the greatest chance of developing this life-threatening disease. Positive cases in New York City had a median age of 62. Those who already have preexisting health problems, such as cancer, diabetes, or hypertension, may be at a greater risk of developing severe further health issues. In extreme cases of West Nile virus, recovering might require several weeks or months, but impairment to the central nervous system can be incurable (<xref ref-type="bibr" rid="ref41">New York Times, 2022</xref>).</p>
<p>The West Nile virus infection should be included in the differential diagnosis, and particular laboratory test findings should raise a high index of clinical suspicion. The IgM-capture enzyme-linked immunosorbent test is the most often applied diagnostic technique. This test has a sensitivity range of 95 to 100% in serum and spinal fluid. The IgM is usually detected in the serum and cerebrospinal fluid by the time the sickness manifests itself. When a person has encephalitis or meningitis, a high IgM of West Nile virus antibodies is undoubtedly indicative of infection; however, the IgM may last for many months to more than a year because humoral IgM antibodies do not penetrate the blood&#x2013;brain barrier, an intrathecal West Nile virus-specific IgM strongly supports a central nervous system infection (<xref ref-type="bibr" rid="ref30">Kemmerly, 2003</xref>).</p>
<p>The clinical care of West Nile virus diseases is considered supportive since neither vaccination nor any drug can be used to treat or prevent West Nile virus in humans. Patients experiencing severe meningeal symptoms typically require pain relief for their headaches, antiemetic treatment, and rehydration for the nausea and vomiting associated with their condition (<xref ref-type="bibr" rid="ref13">CDC, n.d.</xref>).</p>
<p>Although, a huge number of people are affecting in recent time, but no authorized medication or potential vaccine is available still to fight the West Nile virus (<xref ref-type="bibr" rid="ref9">Bergmann et al., 2022</xref>). Therefore, it is of the utmost importance issues to rapidly advance the research and development of potent anti-viral medications to combat this lethal pathogenic viral infection.</p>
<p>To development of a novel drug candidate, required more than 10&#x2009;years of times, huge amount of money and resources (<xref ref-type="bibr" rid="ref47">Rahman et al., 2012</xref>). So, the primary goal of <italic>in silico</italic> research is to develop a drug design strategy to predict the inhibitory activity of a series of natural compounds against West Nile virus with the help of advanced <italic>in silico</italic> method such as molecular docking, molecular dynamics simulations, ADMET, principal component analysis (PCA), dynamics cross-correlation matrices (DCCM) analysis, binding free energy and dynamic cross correlation matrix (DCCM). The molecular docking studies was conducted to determine the binding affinity of the selected phytocompounds with the target proteins of the West Nile virus and then based on maximum affinity, three most potential compounds were carried out to the molecular dynamics simulations and determine the stability and binding energies of the protein-ligand complexes. Ultimately the results of this investigation have the potential to contribute to the development of novel drugs for the treatment of West Nile virus infection.</p>
</sec>
<sec id="sec2">
<label>2.</label>
<title>Literature based evidence</title>
<sec id="sec3">
<label>2.1.</label>
<title>Pharmacological activity of reported compounds in earlier studies and based on which compound are chosen</title>
<sec id="sec4">
<label>2.1.1.</label>
<title>Apigenin pharmacological activity</title>
<p>Apigenin (APG) is a flavonoid found in high concentrations in many fruits, vegetables, and Chinese medicinal herbs. It has a wide range of physiological effects, including anti-inflammatory, antioxidant, antibacterial, anti-viral, and blood pressure-lowering properties (<xref ref-type="bibr" rid="ref64">Yan et al., 2017</xref>). Apigenin has been shown to have anti-cancer, anti-diabetic, and antioxidant effects. APG inhibits tumor cell growth and survival by triggering apoptosis, cell cycle arrest, and the creation of ROS. It also prevents metastasis and angiogenesis by changing various cellular signaling pathways (<xref ref-type="bibr" rid="ref75">Zhou et al., 2022</xref>). APG suppresses Enterovirus-71 infection by interfering with RNA-transacting factor interactions (<xref ref-type="bibr" rid="ref70">Zhang et al., 2014</xref>).</p>
</sec>
<sec id="sec5">
<label>2.1.2.</label>
<title>Resveratrol antiviral activity</title>
<p>Resveratrol is a natural chemical produced by certain plants (<xref ref-type="bibr" rid="ref12">Campagna and Rivas, 2010</xref>). Resveratrol has anti-viral activity against human and animal viruses (<xref ref-type="bibr" rid="ref1">Abba et al., 2015</xref>). Resveratrol has also inhibitory effects on various viruses (<xref ref-type="bibr" rid="ref73">Zhao et al., 2017</xref>).</p>
</sec>
<sec id="sec6">
<label>2.1.3.</label>
<title>Hesperetin pharmacological activity</title>
<p>Hesperetin is a flavanone, and in its water-soluble glycoside form of hesperidin, it can be found in various citrus fruits. Hesperetin has shown anti-viral properties <italic>in vitro</italic> against a few RNA viruses (<xref ref-type="bibr" rid="ref69">Zandi et al., 2011</xref>). Hesperidin also demonstrated anti-viral activity against the growth of the 17D strain of the yellow fever virus (<xref ref-type="bibr" rid="ref3">Agrawal et al., 2021</xref>). The bioflavonoid Hesperetin inhibits the intracellular reproduction of viruses (<xref ref-type="bibr" rid="ref42">Oo et al., 2016</xref>).</p>
</sec>
<sec id="sec7">
<label>2.1.4.</label>
<title>Fungisterol anti-viral activity</title>
<p>Fungisterol, a compound found in mushrooms, has anti-viral properties (<xref ref-type="bibr" rid="ref76">Zhu et al., 2021</xref>). Potential anti-viral effects of Fungisterol have been demonstrated against various pathogens, including the human immunodeficiency virus (HIV), influenza, herpes simplex virus (HSV), hepatitis B and C viruses, and others (<xref ref-type="bibr" rid="ref49">Raut and Adhikari, 2021</xref>).</p>
</sec>
<sec id="sec8">
<label>2.1.5.</label>
<title>Lucidone pharmacological activity</title>
<p>Lucidone is a natural compound found in the fruiting body of the edible mushroom Ganoderma lucidum. It belongs to the class of organic compounds known as coumarins, which are fragrant and sweet-smelling organic compounds that are commonly found in plants (<xref ref-type="bibr" rid="ref10">Boh et al., 2007</xref>). Recent research has been reported that the Lucidone might be composed to have various pharmacological properties, including antioxidant, anti-inflammatory, antitumor, antiviral and neuroprotective activities. It also reported that the Lucidone suppresses dengue viral replication through the induction of heme oxygenase-1 and suppresses Hepatitis C Virus (<xref ref-type="bibr" rid="ref15">Chen et al., 2013</xref>, <xref ref-type="bibr" rid="ref14">2018</xref>).</p>
</sec>
<sec id="sec9">
<label>2.1.6.</label>
<title>Ganoderic acid anti-viral activity</title>
<p>Ganoderic acid (GA) has been shown to have anti-viral, antihypertensive, anti-cancer, and immune-modulatory effects (<xref ref-type="bibr" rid="ref76">Zhu et al., 2021</xref>). Anti-viral effects of Ganoderic acid against Enterovirus 71 (EV71) infection are observed without cytotoxicity (<xref ref-type="bibr" rid="ref71">Zhang et al., 2014</xref>). There is evidence that Ganoderic acid can inhibit viral replication and reduce the extent of liver damage (<xref ref-type="bibr" rid="ref38">Li and Wang, 2006</xref>).</p>
</sec>
<sec id="sec10">
<label>2.1.7.</label>
<title>Curcumin pharmacological activity</title>
<p>It has also been demonstrated that Curcumin prevents the development of several viruses and cancerous cells. Curcumin can block the production of HSV-1&#x2019;s immediate early genes and the action of the HIV-1 integrase, both of which are required for the virus&#x2019;s replication (<xref ref-type="bibr" rid="ref68">Zandi et al., 2010</xref>). Through mechanisms present in the infected cells, Curcumin can stop the production of viral genes and, consequently, viral replication (<xref ref-type="bibr" rid="ref37">Kutluay et al., 2008</xref>).</p>
</sec>
<sec id="sec11">
<label>2.1.8.</label>
<title>Kaempferol pharmacological activity</title>
<p>Previous reports indicate flavanol Kaempferol and its glycosides have strong anti-viral properties (<xref ref-type="bibr" rid="ref31">Khazdair et al., 2021</xref>). Kaempferol could prevent the spread of viruses in the brain, lungs, kidneys, heart, and spleen. According to research, the hepatitis B virus, the H1N1 and H9N2 influenza viruses, and the Herpes simplex virus are all susceptible to the effects of Kaempferol (<xref ref-type="bibr" rid="ref72">Zhang et al., 2012</xref>; <xref ref-type="bibr" rid="ref48">Rahman et al., 2022</xref>).</p>
</sec>
<sec id="sec12">
<label>2.1.9.</label>
<title>Cholic acid pharmacological activity</title>
<p>Since both Cholic acid and metal ions have pharmacological effects, such as antibacterial, anti-viral, antifungal, antimalarial, antitubercular, anti-cancer, spermicidal, and antiallergic, their organometallic complexes were created to have a synergistic effect (<xref ref-type="bibr" rid="ref32">Kishu and Siva, 2011</xref>). It has been found that several cholic acid derivatives, including taurolithocholic acid, lithocholic acid 3-sulfate, and taurolithocholic acid 3-sulfate, preferentially suppress type 1 human immunodeficiency virus replication (HIV-1) (<xref ref-type="bibr" rid="ref8">Baba et al., 1989</xref>). Cholic acid can be prevented Coxsackievirus B3 recurrence and produce anti-viral activity (<xref ref-type="bibr" rid="ref24">Han et al., 2018</xref>).</p>
</sec>
<sec id="sec13">
<label>2.1.10.</label>
<title>Chlorogenic acid pharmacological activity</title>
<p>Chlorogenic acid is a widely distributed natural chemical with numerous significant pharmacological actions, including antioxidant, anti-inflammatory, antibacterial, anti-viral, hypoglycemic, lipid-lowering, anti-cardiovascular, antimutagenic, anti-cancer, and immunomodulatory (<xref ref-type="bibr" rid="ref40">Naveed et al., 2018</xref>). Chlorogenic acid (CHA) treats viral upper respiratory tract infections brought on by influenza, parainfluenza, and respiratory syncytial viruses (<xref ref-type="bibr" rid="ref17">Ding et al., 2017</xref>). Besides, another <italic>in silico</italic> investigation has reported that Chlorogenic acid might be effective against SARS-CoV-2 (<xref ref-type="bibr" rid="ref5">Aini et al., 2022</xref>).</p>
</sec>
<sec id="sec14">
<label>2.1.11.</label>
<title>Pinocembrin pharmacological activity</title>
<p>Pinocembrin demonstrated potent antifungal action in a dose-dependent manner against <italic>Penicillium italicum</italic> (<xref ref-type="bibr" rid="ref44">Peng et al., 2012</xref>). Pinocembrin exhibits anti-viral activity against the reproduction of the Zika virus (<xref ref-type="bibr" rid="ref21">Ghildiyal et al., 2020</xref>; <xref ref-type="bibr" rid="ref27">Huang et al., 2022</xref>). Pinocembrin inhibits the Zika virus replication cycle&#x2019;s post-entry process, and also, it also prevents the formation of viral envelope protein and RNA (<xref ref-type="bibr" rid="ref23">Guang and Du, 2006</xref>).</p>
</sec>
<sec id="sec15">
<label>2.1.12.</label>
<title>Sanguinarine pharmacological activity</title>
<p>Sanguinarine is a plant alkaloid with considerable antiangiogenic, anti-cancer, and anti-viral potential but comparatively moderate toxicity (<xref ref-type="bibr" rid="ref20">Feldman et al., 2018</xref>). Sanguinarine promotes anti-viral activity by upregulating TLR expression and its downstream mediator in MDM (<xref ref-type="bibr" rid="ref59">Tilgner and Shi, 2004</xref>). It demonstrated selectivity for MKP-1 over MKP-3, inhibiting cellular MKP-1 with an IC<sub>50</sub> of 10&#x2009;m (<xref ref-type="bibr" rid="ref23">Guang and Du, 2006</xref>).</p>
<p>Below <xref rid="fig1" ref-type="fig">Figure 1</xref> has shown the chemical structures of studied compounds and <xref rid="tab1" ref-type="table">Table 1</xref> displayed the pharmacological evidence more precisely.</p>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption><p>Chemical structures of studied compounds.</p></caption>
<graphic xlink:href="fmicb-14-1189786-g001.tif"/>
</fig>
<table-wrap position="float" id="tab1">
<label>Table 1</label>
<caption><p>Experimental and clinical data on the anti-viral activities of natural compounds against viral strains have been reported in different research investigations.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Drug name</th>
<th align="left" valign="top">Anti-viral activity</th>
<th align="left" valign="top">References</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Apigenin</td>
<td align="left" valign="top">Apigenin suppresses enterovirus-71 infection by interfering with RNA-transacting factor interactions</td>
<td align="left" valign="top"><xref ref-type="bibr" rid="ref70">Zhang et al. (2014)</xref></td>
</tr>
<tr>
<td align="left" valign="top">Resveratrol</td>
<td align="left" valign="top">Resveratrol effectively reduced the cytopathogenic the action of AD virus type 7</td>
<td align="left" valign="top"><xref ref-type="bibr" rid="ref22">Guan et al. (2008)</xref></td>
</tr>
<tr>
<td align="left" valign="top">Hesperetin</td>
<td align="left" valign="top">Hesperetin inhibits the intracellular reproduction of viruses</td>
<td align="left" valign="top"><xref ref-type="bibr" rid="ref42">Oo et al. (2016)</xref></td>
</tr>
<tr>
<td align="left" valign="top">Fungisterol</td>
<td align="left" valign="top">Fungisterol&#x2019;s anti-viral properties related to the polysaccharides present in the mycelium and fruiting bodies</td>
<td align="left" valign="top"><xref ref-type="bibr" rid="ref49">Raut and Adhikari (2021)</xref></td>
</tr>
<tr>
<td align="left" valign="top">Lucidone</td>
<td align="left" valign="top">Lucidone inhibits DENV protein production</td>
<td align="left" valign="top"><xref ref-type="bibr" rid="ref53">Senthil Kumar and Wang (2016)</xref></td>
</tr>
<tr>
<td align="left" valign="top">Ganoderic acid</td>
<td align="left" valign="top">Ganoderic acid are effective against human immunodeficiency virus type 1 (HIV-1)</td>
<td align="left" valign="top"><xref ref-type="bibr" rid="ref39">Lindequist et al. (2005)</xref></td>
</tr>
<tr>
<td align="left" valign="top">Curcumin</td>
<td align="left" valign="top">Curcumin prevented colon cancer cell lines (HT-29 and HCT-15) from proliferating by gathering cells in the G2-M phase</td>
<td align="left" valign="top"><xref ref-type="bibr" rid="ref57">Syng-Ai et al. (2004)</xref></td>
</tr>
<tr>
<td align="left" valign="top">Kaempferol</td>
<td align="left" valign="top">The 3a channel can be blocked by kaempferol and kaempferol glycosides, providing anti-viral action.</td>
<td align="left" valign="top"><xref ref-type="bibr" rid="ref52">Schwarz et al. (2014)</xref></td>
</tr>
<tr>
<td align="left" valign="top">Cholic acid</td>
<td align="left" valign="top">Cholic acid suppresses type 1 human immunodeficiency virus replication (HIV-1)</td>
<td align="left" valign="top"><xref ref-type="bibr" rid="ref8">Baba et al. (1989)</xref></td>
</tr>
<tr>
<td align="left" valign="top">Chlorogenic acid</td>
<td align="left" valign="top">Chlorogenic acid in reducing the HBV DNA relapse</td>
<td align="left" valign="top"><xref ref-type="bibr" rid="ref78">Zuo et al. (2015)</xref></td>
</tr>
<tr>
<td align="left" valign="top">Pinocembrin</td>
<td align="left" valign="top">Pinocembrin prevents the formation of viral envelope protein and RNA</td>
<td align="left" valign="top"><xref ref-type="bibr" rid="ref23">Guang and Du (2006)</xref></td>
</tr>
<tr>
<td align="left" valign="top">Sanguinarine</td>
<td align="left" valign="top">Sanguinarine promotes an anti-viral activity by upregulating TLR expression and its downstream mediator in MDM</td>
<td align="left" valign="top"><xref ref-type="bibr" rid="ref56">Sunthamala et al. (2020)</xref></td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
</sec>
<sec id="sec16">
<label>2.2.</label>
<title>Genome and physiological characteristics</title>
<p>The genus Flavivirus, of the family Flaviviridae, is host to the West Nile virus. Flavivirus virions are round and have a diameter of around 50&#x2009;nm. The viral envelope and membrane proteins are encased in a lipid bilayer surrounding the nucleocapsid (roughly 30&#x2009;nm in diameter and composed of capsid protein and genomic RNA). The virion has a single, plus-sense RNA genome about 11 kilobases in length and is divided into a 5&#x2032; untranslated region (UTR). The conserved dinucleotide AG follows the 5&#x2032; caps of the flavivirus genome, and the conserved dinucleotide CUOH finishes off the 3&#x2032; ends of the genome. The 5&#x2032; UTR and 3&#x2032; UTR of genomic RNA each have a length of about 100 and 500 to 700 nucleotides, respectively. Viral and cellular proteases co-translate and post-translate the encoded polyprotein into seven nonstructural proteins (NS1, NS2a, NS2b, NS3, NS4a, and NS5) and three structural proteins (capsid, pre-membrane or transmembrane, and envelope). The nonstructural proteins function primarily as replication complex components to ensure the successful replication of viral RNA. For RNA replication to take place, NS1 must interact with NS4a. Hydrophobic NS2a was shown to have a role in flavivirus particle formation and release. With NS3, NS2b generated a complex essential for NS3&#x2019;s serine protease activity. A serine protease, 5&#x2032;-RNA triphosphatase, nucleoside triphosphatase, and RNA helicase are all functions of NS3, a multifunctional protein. Yet, the roles of NS4a and NS4b, two membrane-associated proteins, remain unknown. The NS5 protein is an RNA-dependent RNA polymerase and a methyltransferase that modifies the 5&#x2019; RNA cap structure. When a flavivirus replicates, a replication complex is assembled on the 3&#x2032; UTR of the genomic RNA during the process of co-translation. When the positive-sense RNA is copied, the resulting negative-sense RNA is still base-paired with the original replicative form (RF). After that, the RF is reused as a starting point for the asymmetric production of more positive-sense RNA (<xref rid="fig2" ref-type="fig">Figure 2</xref>) (<xref ref-type="bibr" rid="ref59">Tilgner and Shi, 2004</xref>).</p>
<fig position="float" id="fig2">
<label>Figure 2</label>
<caption><p>Structure of West Nile Virus.</p></caption>
<graphic xlink:href="fmicb-14-1189786-g002.tif"/>
</fig>
</sec>
<sec id="sec17">
<label>2.3.</label>
<title>Transmission and clinical manifestation</title>
<p>The West Nile virus infection is a mosquito-borne disease that may infect people, birds, and animals. According to the CDC, the primary host for the virus is birds, and mosquitoes acquire the virus by biting affected birds. Health experts have announced that it cannot be transmitted from direct contact from person to person (<xref ref-type="bibr" rid="ref26">West Nile Virus Found in Another NY County, Bringing Case Total to 5, n.d.</xref>). <xref rid="fig3" ref-type="fig">Figure 3</xref> displays the transmission routes of the West Nile virus.</p>
<fig position="float" id="fig3">
<label>Figure 3</label>
<caption><p>The West Nile virus transmission from animals to humans. When an infected mosquito bites an animal or a person (the &#x201C;host&#x201D;), the virus is introduced into the host&#x2019;s circulation and has the potential to severely sick the host. The virus enters the circulation of the mosquito when an infected bird bites it and ultimately travels to its salivary glands.</p></caption>
<graphic xlink:href="fmicb-14-1189786-g003.tif"/>
</fig>
</sec>
</sec>
<sec id="sec18">
<label>3.</label>
<title>Computational method and material</title>
<sec id="sec19">
<label>3.1.</label>
<title>Preparation of ligand and geometry optimization</title>
<p>By utilizing vibrational frequency from the DMol3 code of Material Studio 08, a method known as DFT functional was used to accomplish molecular optimization (<xref ref-type="bibr" rid="ref66">Yuan et al., 2016</xref>; <xref ref-type="bibr" rid="ref35">Kumer et al., 2021</xref>). The molecular optimization was performed to produce exceptionally accurate results during molecular docking. After optimizing, chemical compounds were generated as a pdb file for molecular docking, drug-likeness, and ADMET (<xref rid="fig4" ref-type="fig">Figure 4</xref>).</p>
<fig position="float" id="fig4">
<label>Figure 4</label>
<caption><p>Optimized structure of reported natural compounds.</p></caption>
<graphic xlink:href="fmicb-14-1189786-g004.tif"/>
</fig>
</sec>
<sec id="sec20">
<label>3.2.</label>
<title>Determination of ADMET, Lipinski rule, and drug-likeness</title>
<p>To assess their drug likeliness, we examine the ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) pharmacological characteristics of chosen compounds (<xref ref-type="bibr" rid="ref63">Wijaya et al., 2021</xref>). With the aid of ADMET, we may predict if a molecule will be successfully implemented while designing new drugs based on their pharmacokinetics qualities. The pkCSM web server and Swiss-ADME were employed for this (<xref ref-type="bibr" rid="ref4">AI Azzam, 2023</xref>). The Lipinski rule violation, GI (gastrointestinal) absorption, BBB penetration, and solubility are some of the pharmacological issues discussed by the Swiss-ADME online-based web server.<xref rid="fn0004" ref-type="fn"><sup>1</sup></xref> We research our compound&#x2019;s excretion and toxicity using the pkCSM web server (<xref ref-type="bibr" rid="ref16">Daina et al., 2017</xref>; <xref ref-type="bibr" rid="ref63">Wijaya et al., 2021</xref>).<xref rid="fn0005" ref-type="fn"><sup>2</sup></xref> Drug likeness is one of a drug compound&#x2019;s sensory attributes that is frequently used in the drug discovery process. When Lipinski and colleagues released the rule of 5 (Ro5) in 1997, it was based on research of 2,245 drug qualities from the World Drug Index (WDI) databank that had been accepted for phase 2 clinical trials (<xref ref-type="bibr" rid="ref50">Sadowski and Kubinyi, 1998</xref>; <xref ref-type="bibr" rid="ref6">Akash, 2022</xref>). This was the first time that pharmacokinetic properties had been approached academically. Molecular weight, the amount of hydrogen bond donors and acceptors, topological polar surface area, consensus log Po/w, and drug similarity features such as lipinski rule violation and synthesis accessibility is all examined in this section.</p>
</sec>
<sec id="sec21">
<label>3.3.</label>
<title>Protein preparation, molecular docking analysis</title>
<p>The crystal structure of several west Nile virus strains was retrieved from the Protein Data Bank (PDB) of the RCSB Protein online portal (<xref ref-type="bibr" rid="ref11">Burley et al., 2017</xref>). Protein purification was carried out carefully by removing ligands and water using Pymol v2.4.1 software<xref rid="fn0006" ref-type="fn"><sup>3</sup></xref> (<xref ref-type="bibr" rid="ref43">Padmi et al., 2022</xref>) (illustrated in <xref rid="fig5" ref-type="fig">Figure 5</xref>). The crystal structure of the cleaned protein file is fed into AutoDock tools after the extra water and ligand have been removed, and the instructions are followed to create the pdbqt file format (<xref ref-type="bibr" rid="ref65">Yuan et al., 2017</xref>; <xref ref-type="bibr" rid="ref36">Kumer et al., 2022</xref>).</p>
<fig position="float" id="fig5">
<label>Figure 5</label>
<caption><p>Details information about studied proteins. <bold>(A)</bold> West Nile virus methyltransferase (PDB ID 2OY0). Organism: West Nile virus. Method: X-ray diffraction. Resolution: 2.80 (<xref ref-type="bibr" rid="ref74">Zhou et al., 2007</xref>). <bold>(B)</bold> West Nile virus envelope glycoprotein (PDB ID 2I69). Organism: West Nile virus. Method: X-ray diffraction. Resolution: 3.11 (<xref ref-type="bibr" rid="ref28">Kanai et al., 2006</xref>).</p></caption>
<graphic xlink:href="fmicb-14-1189786-g005.tif"/>
</fig>
<p>The development of the binding affinity of molecular complex may be predicted <italic>via</italic> the use of a computer approach known as &#x201C;<italic>in silico</italic> molecular docking&#x201D; (<xref ref-type="bibr" rid="ref2">Agarwal and Mehrotra, 2016</xref>). In current studies, the PyRx AutoDock vina tool is applied for molecular docking. Before, performing docking, previously prepared drug, and protein were uploaded in PyRx application, and converted them as autodocking protein, and autodocking protein. Finally, specified grid parameter were selected, and perform the molecular docking studies (<xref ref-type="bibr" rid="ref67">Yuliana et al., 2013</xref>).</p>
</sec>
<sec id="sec22">
<label>3.4.</label>
<title>Molecular dynamic simulations (MDs) methods</title>
<p>MD modeling is used to study the movement of molecules and atoms in dynamic systems, like protein-ligand complexes, in order to understand important physicochemical phenomena. MD simulations were run using receptor-ligand complexes acquired <italic>via</italic> molecular docking research to verify the binding mechanism and stability in a dynamic system. For this purpose, three best-docked compounds were subjected to 100&#x2009;ns MD simulations: apigenin and curcumin against the West Nile virus methyltransferase with PDB ID 2OY0 as the target receptor, and Ganoderic acid against the West Nile virus envelope glycoprotein (PDB ID 2I69) target receptor. The simulation system was set up using the CHARMM-GUI web-based graphical interface and produced the force field for both the ligands and the proteins (<xref ref-type="bibr" rid="ref62">Wang et al., 2019</xref>). In the simulations that were carried out for 100&#x2009;ns inside a periodic water box, the CHARMM36 force field and the Gromacs version 2020 software package were both utilized (<xref ref-type="bibr" rid="ref7">Akash et al., 2022</xref>; <xref ref-type="bibr" rid="ref58">Terefe and Ghosh, 2022</xref>). The complexes were positioned within a rectangular box that had a buffer distance of 10 in each of the cardinal directions. The box was subsequently dissolved in water molecules containing TIP3P. To keep the systems neutral, sodium and chloride ions were introduced, and then the energy was minimized using the steepest descent approach. Equilibration was performed on each of the complete systems at a temperature of 310&#x2009;K for a total of 5,000 steps (i.e., 10 PS). The NPT ensemble&#x2019;s performance lasted 100&#x2009;s. The Lincs technique was used to place constraints on hydrogen, and as a result, the timestep was set at 2&#x2009;fs. All van der Waals forces were calculated using a switching method between 12 and 14, and 14 was found to be the cutoff value. The particle mesh Ewald (PME) method with a maximum grid spacing of 1.2 was used to figure out the long-range electrostatic interactions. No multiple-time-stepping strategy was used; instead, PME computations were performed at each step. At a temperature of 310 kelvin, the initial velocities were chosen at random from a Maxwellian distribution. The temperature was maintained at 310&#x2009;K. The barostat was programmed to have a target of 1&#x2009;bar for any system size changes that occurred. The integration time step was 2&#x2009;fs. After then, the simulation&#x2019;s output was re-centered, and the trajectories were subsequently assessed using the VMD (University of Illinois at Urbana-Champaign, Urbana, IL, USA) program, Bio3D, and QTGRACE, respectively. In the investigation of the system&#x2019;s stability, the root means square deviation (RMSD), the root means square fluctuation (RMSF), the radius of gyration (Rg), the number of hydrogen bonds, and the principal component analysis were taken into consideration (<xref ref-type="bibr" rid="ref61">Walters, 2012</xref>).</p>
</sec>
<sec id="sec23">
<label>3.5.</label>
<title>Binding free energy calculation using MM-PBSA</title>
<p>In the molecular dynamics simulation, free energy calculation takes a major role in determining the binding energy of ligands inside proteins (<xref ref-type="bibr" rid="ref77">Zikri et al., 2020</xref>). In this investigation, the MM-PBSA method was used to calculate the free interaction energy between ligands and West Nile virus methyltransferase (PDB ID 2OY0) and West Nile virus envelope glycoprotein (PDB ID 2I69). Calculations using MM-PBSA were performed to determine the binding affinity of protein-ligand complexes. Binding free energy (&#x0394;G) estimation was done by eq. (3) using the script MMPBSA.py of the AMBER package (<xref ref-type="bibr" rid="ref62">Wang et al., 2019</xref>).</p>
<disp-formula id="E1"><label>(1)</label><mml:math id="M1"><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi mathvariant="normal">&#x0394;</mml:mi><mml:mtext>Gbind</mml:mtext><mml:mspace width="thickmathspace"/><mml:mi mathvariant="normal">G</mml:mi><mml:mo>=</mml:mo><mml:mo>&#x2212;</mml:mo><mml:mtext>complex</mml:mtext><mml:mspace width="thickmathspace"/><mml:mi mathvariant="normal">G</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mtext>protein</mml:mtext><mml:mspace width="thickmathspace"/><mml:mi mathvariant="normal">G</mml:mi><mml:mo>&#x2212;</mml:mo><mml:mtext>ligand</mml:mtext></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>
<p>G-complex is the free energy of the complex; G-receptor is the free energy of the receptor; G-ligand is the free energy of the ligand (<xref ref-type="bibr" rid="ref58">Terefe and Ghosh, 2022</xref>).</p>
</sec>
</sec>
<sec id="sec24">
<label>4.</label>
<title>Result and analysis</title>
<sec id="sec25">
<label>4.1.</label>
<title>Lipinski rule, pharmacokinetics</title>
<p>The Lipinski rule and drug resemblance give important details about the initial stages of medication development and raise the probability of success. According to the Lipinski rule of five, the drug&#x2019;s permeability and bioavailability depend on the molecular weight, the number of hydrogen bond donors and acceptors, and Topological polar surface area (&#x00C5;<sup>2</sup>). The six-ligand compound can successfully pass the Lipinski rule of five without any violations (<xref ref-type="bibr" rid="ref61">Walters, 2012</xref>; <xref ref-type="bibr" rid="ref7">Akash et al., 2022</xref>). However, the other six ligand compound cannot satisfy by Lipinski rule. Besides, low-molecular-weight ligand compounds are more readily absorbed, dispersed, and transported than those with greater molecular weights (<xref ref-type="bibr" rid="ref51">Santos et al., 2016</xref>). The polarity of a ligand compound can be determined by a molecule&#x2019;s topological polar surface area (TPSA), which is a significant pharmacokinetics feature. These values help describe the drug transport characteristics. All polar atoms, primarily oxygen and nitrogen with connected hydrogen, make up the polar surface area of molecules. All our ligands showed very promising pharmacokinetics properties shown in the <xref rid="tab2" ref-type="table">Table 2</xref>.</p>
<table-wrap position="float" id="tab2">
<label>Table 2</label>
<caption><p>Predicted data of Lipinski rule, pharmacokinetics.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top" rowspan="2">No.</th>
<th align="center" valign="top" rowspan="2">Weight (g/mol)</th>
<th align="center" valign="top" rowspan="2">Hydrogen bond acceptor</th>
<th align="center" valign="top" rowspan="2">Hydrogen bond donor</th>
<th align="center" valign="top" rowspan="2">Topological polar surface area (&#x00C5;<sup>2</sup>)</th>
<th align="center" valign="top" colspan="2">Lipinski rule</th>
</tr>
<tr>
<th align="center" valign="top">Result</th>
<th align="center" valign="top">Violations</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">01</td>
<td align="center" valign="middle">270.24</td>
<td align="center" valign="middle">05</td>
<td align="center" valign="middle">03</td>
<td align="center" valign="middle">90.90</td>
<td align="center" valign="middle">Yes</td>
<td align="center" valign="middle">00</td>
</tr>
<tr>
<td align="left" valign="middle">02</td>
<td align="center" valign="middle">228.24</td>
<td align="center" valign="middle">03</td>
<td align="center" valign="middle">03</td>
<td align="center" valign="middle">60.69</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">01</td>
</tr>
<tr>
<td align="left" valign="middle">03</td>
<td align="center" valign="middle">302.28</td>
<td align="center" valign="middle">06</td>
<td align="center" valign="middle">03</td>
<td align="center" valign="middle">96.22</td>
<td align="center" valign="middle">Yes</td>
<td align="center" valign="middle">00</td>
</tr>
<tr>
<td align="left" valign="middle">04</td>
<td align="center" valign="middle">400.68</td>
<td align="center" valign="middle">01</td>
<td align="center" valign="middle">01</td>
<td align="center" valign="middle">20.23</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">02</td>
</tr>
<tr>
<td align="left" valign="middle">05</td>
<td align="center" valign="middle">70.18</td>
<td align="center" valign="middle">04</td>
<td align="center" valign="middle">01</td>
<td align="center" valign="middle">63.60</td>
<td align="center" valign="middle">Yes</td>
<td align="center" valign="middle">00</td>
</tr>
<tr>
<td align="left" valign="middle">06</td>
<td align="center" valign="middle">368.38</td>
<td align="center" valign="middle">06</td>
<td align="center" valign="middle">02</td>
<td align="center" valign="middle">93.06</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">02</td>
</tr>
<tr>
<td align="left" valign="middle">07</td>
<td align="center" valign="middle">368.38</td>
<td align="center" valign="middle">06</td>
<td align="center" valign="middle">02</td>
<td align="center" valign="middle">93.06</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">02</td>
</tr>
<tr>
<td align="left" valign="middle">08</td>
<td align="center" valign="middle">286.24</td>
<td align="center" valign="middle">06</td>
<td align="center" valign="middle">04</td>
<td align="center" valign="middle">111.13</td>
<td align="center" valign="middle">Yes</td>
<td align="center" valign="middle">00</td>
</tr>
<tr>
<td align="left" valign="middle">09</td>
<td align="center" valign="middle">408.57</td>
<td align="center" valign="middle">05</td>
<td align="center" valign="middle">04</td>
<td align="center" valign="middle">97.99</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">01</td>
</tr>
<tr>
<td align="left" valign="middle">10</td>
<td align="center" valign="middle">354.31</td>
<td align="center" valign="middle">09</td>
<td align="center" valign="middle">06</td>
<td align="center" valign="middle">164.75</td>
<td align="center" valign="middle">Yes</td>
<td align="center" valign="middle">01</td>
</tr>
<tr>
<td align="left" valign="middle">11</td>
<td align="center" valign="middle">256.25</td>
<td align="center" valign="middle">04</td>
<td align="center" valign="middle">02</td>
<td align="center" valign="middle">66.76</td>
<td align="center" valign="middle">Yes</td>
<td align="center" valign="middle">00</td>
</tr>
<tr>
<td align="left" valign="middle">12</td>
<td align="center" valign="middle">332.33</td>
<td align="center" valign="middle">04</td>
<td align="center" valign="middle">00</td>
<td align="center" valign="middle">40.80</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">01</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="sec26">
<label>4.2.</label>
<title>Molecular docking analysis against West Nile virus</title>
<p>One of the core technologies in computer-aided drug design is molecular docking, which allows for the analysis of protein-ligand complexes&#x2019; non-bond interactions and energy bindings. Several natural compound derivatives were studied to attach molecularly with the target receptor protein of the West Nile virus. Molecular docking has been used to obtain specific information on protein-ligand complexes&#x2019; interaction and binding affinity. The compounds were evaluated by utilizing the interaction with the maximum binding affinity scores. The use of computer-based docking studies in drug design is essential because it enables examination of the ligand configuration with the receptor protein&#x2019;s active site and investigation of non-bond interaction. Typically, it was believed that a pharmaceutical drug&#x2019;s effective binding affinity was &#x2212;6.00&#x2009;kcal/mol is expected (<xref ref-type="bibr" rid="ref29">Kawsar et al., 2022</xref>; <xref ref-type="bibr" rid="ref46">Rahman et al., 2022</xref>). The most incredible binding energy for the West Nile virus methyltransferase with (PDB ID: 2OY0) target receptor is &#x2212;8.3&#x2009;kcal/mole, whereas the maximum binding energy for the West Nile virus envelope glycoprotein with (PDB ID: 2I69) target receptor is &#x2212;8.1&#x2009;kcal/mol, as observed in molecules 04 and 20 of our medication (<xref rid="tab3" ref-type="table">Table 3</xref>). That suggests our pharmacological compound is working more effectively against these two targets. As a result, our therapeutic molecule may be particularly successful in treating West Nile virus infection.</p>
<table-wrap position="float" id="tab3">
<label>Table 3</label>
<caption><p>Summary of binding affinities.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top" rowspan="2">No.</th>
<th align="left" valign="top" rowspan="2">Name</th>
<th align="center" valign="top">West Nile virus methyltransferase (PDB ID 2OY0)</th>
<th align="center" valign="top">West Nile virus envelope glycoprotein (PDB ID 2I69)</th>
</tr>
<tr>
<th align="center" valign="top">Binding Affinity (kcal/mol)</th>
<th align="center" valign="top">Binding Affinity(kcal/mol)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">01</td>
<td align="left" valign="top">Apigenin</td>
<td align="center" valign="top">&#x2212;8.5</td>
<td align="center" valign="top">&#x2212;7.5</td>
</tr>
<tr>
<td align="left" valign="top">02</td>
<td align="left" valign="top">Resveratrol</td>
<td align="center" valign="top">&#x2212;7.7</td>
<td align="center" valign="top">&#x2212;7.2</td>
</tr>
<tr>
<td align="left" valign="top">03</td>
<td align="left" valign="top">Hesperetin</td>
<td align="center" valign="top">&#x2212;8.0</td>
<td align="center" valign="top">&#x2212;7.1</td>
</tr>
<tr>
<td align="left" valign="top">04</td>
<td align="left" valign="top">Fungisterol</td>
<td align="center" valign="top">&#x2212;7.4</td>
<td align="center" valign="top">&#x2212;7.0</td>
</tr>
<tr>
<td align="left" valign="top">05</td>
<td align="left" valign="top">Lucidone</td>
<td align="center" valign="top">&#x2212;7.8</td>
<td align="center" valign="top">&#x2212;7.4</td>
</tr>
<tr>
<td align="left" valign="top">06</td>
<td align="left" valign="top">Ganoderic acid</td>
<td align="center" valign="top">&#x2212;7.6</td>
<td align="center" valign="top">&#x2212;8.0</td>
</tr>
<tr>
<td align="left" valign="top">07</td>
<td align="left" valign="top">Curcumin</td>
<td align="center" valign="top">&#x2212;8.3</td>
<td align="center" valign="top">&#x2212;7.3</td>
</tr>
<tr>
<td align="left" valign="top">08</td>
<td align="left" valign="top">Kaempferol</td>
<td align="center" valign="top">&#x2212;8.1</td>
<td align="center" valign="top">&#x2212;6.8</td>
</tr>
<tr>
<td align="left" valign="top">09</td>
<td align="left" valign="top">Cholic acid</td>
<td align="center" valign="top">&#x2212;7.9</td>
<td align="center" valign="top">&#x2212;7.6</td>
</tr>
<tr>
<td align="left" valign="top">10</td>
<td align="left" valign="top">Chlorogenic acid</td>
<td align="center" valign="top">&#x2212;8.0</td>
<td align="center" valign="top">&#x2212;7.1</td>
</tr>
<tr>
<td align="left" valign="top">11</td>
<td align="left" valign="top">Pinocembrin</td>
<td align="center" valign="top">&#x2212;7.5</td>
<td align="center" valign="top">&#x2212;6.5</td>
</tr>
<tr>
<td align="left" valign="top">12</td>
<td align="left" valign="top">Sanguinarine</td>
<td align="center" valign="top">&#x2212;7.2</td>
<td align="center" valign="top">&#x2212;6.7</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="sec27">
<label>4.3.</label>
<title>Protein-ligand interaction valuation</title>
<p>Docking studies of West Nile virus methyltransferase (PDB ID 2OY0) have revealed that drugs like Apigenin, and Curcumin, had the greatest binding score. On the other hand, compounds such as Ganoderic acid, and Cholic acid have been found to dock with the West Nile virus envelope glycoprotein (PDB ID: 2I69) with the highest binding score. So, the protein-ligand interaction valuation of these mentioned compounds was carried out by BIOVIA Discovery Studio 2016 v16.1.0 and Pymol v2.4.1 software (<xref ref-type="bibr" rid="ref60">Wahyuni et al., 2022</xref>). Curcumin&#x2019;s binding sites are located at LYS-A:105 and ILE-A:147 on West Nile virus methyltransferase (PDB ID 2OY0), Apigenin binding site are found at VAL-A:132, ASP-A:131, PHE-A:133, LYS-A:105, ASP-A:146, TRP-A:87, GLY-A:58, ASP-A: 79. On the other hand, Ganoderic acid binding sites are located at PRO-A:339, VAL-A:304, LYS-A:337, ARG-A:338, VAL-A:385, VAL-A:343, ASA-A:347. Cholic acid binding sites are located at LE-A:340, VAL-A:358, VAL-A:304, LYS-A:337, SER-A:341, and PRO-A:339. Sanguinarine binding sites are located at ALA-A:161, PRO-A:146, SER-A:363, VAL-A:364, ALA-A:369, LYS-A:370, and THR-A:148. This active side was predicted by discovery studio 2021 (<xref ref-type="bibr" rid="ref34">Kumer et al., 2022</xref>).</p>
<p>Besides, Un-ionized medications are administration into the body more effectively than their ionized counterparts, which are also known as charged drugs. A drug that is a weak acid will be absorbed predominantly in the acidic medium if it is administered orally; on the other hand, a drug that is a weak base will be captured in the alkaline system of the small intestines if it is administered orally (<xref ref-type="bibr" rid="ref54">Song et al., 2004</xref>; <xref ref-type="bibr" rid="ref33">Kumar et al., 2013</xref>). In (6C, as depicted in <xref rid="fig6" ref-type="fig">Figure 6</xref>) ionizability is displayed. The red color represented basicity, and sky-blue represented acidic condition while the deep blue color means neutral condition. According to the study, it is seen that most of the drugs are slightly basic in nature, which means they may better absorption rate in basic medium.</p>
<fig position="float" id="fig6">
<label>Figure 6</label>
<caption><p>Docking pocket, active side (Amino acid residues), and ionizability.</p></caption>
<graphic xlink:href="fmicb-14-1189786-g006.tif"/>
</fig>
</sec>
<sec id="sec28">
<label>4.4.</label>
<title>MD simulation results</title>
<p>The molecular dynamics simulation was launched to comprehend the stability of the complex in depth. This approach is essential for understanding the structure&#x2013;function relationship of macromolecules. In this study, Apigenin, Curcumin, and Ganoderic Acid were determined to be the best leaders among all the natural compounds evaluated due to their consistent performance in terms of docking score and protein-ligand interactions. To validate this further, the docked complexes of selected compounds, i.e., apigenin and curcumin with West Nile virus methyltransferase (PDB ID 2OY0) and Ganoderic acid with West Nile virus envelope glycoprotein (PDB ID 2I69), were studied for the complexes&#x2019; stability and intermolecular interaction with respect to time by 100&#x2009;ns molecular dynamics (MD) simulation. When simulations were completed, the root mean square deviation (RMSD), root mean square fluctuation (RMSF), the radius of gyration (Rg), H-bond analysis, and principal component analysis (PCA) were determined for each frame of the trajectory.</p>
<sec id="sec29">
<label>4.4.1.</label>
<title>Study of stability using root mean square deviation</title>
<p>RMSD refers to the occurrence of deviations that were noticed during the evolution of the simulation (<xref ref-type="bibr" rid="ref44">Peng et al., 2012</xref>; <xref ref-type="bibr" rid="ref21">Ghildiyal et al., 2020</xref>; <xref ref-type="bibr" rid="ref27">Huang et al., 2022</xref>). Furthermore, the RMSD defines the stability of the structural as the smaller the RMSD, the greater the stability (<xref ref-type="bibr" rid="ref27">Huang et al., 2022</xref>). RMSD calculations for protein backbones, ligands, and complexes during a100 ns MD simulation of each protein-ligand complex were used to get an insight into conformational changes during protein-ligand interactions, as shown in <xref rid="fig7" ref-type="fig">Figure 7</xref>.</p>
<fig position="float" id="fig7">
<label>Figure 7</label>
<caption><p>RMSD plots after 100&#x2009;ns run. <bold>(A)</bold> <italic>Apigenin</italic> against West Nile virus methyltransferase (PDB ID 2OY0). <bold>(B)</bold> <italic>Curcumin</italic> against West Nile virus methyltransferase (PDB ID 2OY0). <bold>(C)</bold> <italic>Ganoderic acid</italic> against West Nile virus envelope glycoprotein (PDB ID 2169).</p></caption>
<graphic xlink:href="fmicb-14-1189786-g007.tif"/>
</fig>
<p>Derived from a 100&#x2009;ns MD simulation, the RMSD of the ligand, protein backbone, and complex RMSD values for apigenin, curcumin, and Ganoderic acid are displayed. The RMSD of the protein backbone is displayed in red. The complex RMSD (root-mean-square deviation) is depicted in black. The RMSD (root mean square deviation) of the ligand is depicted in green.</p>
<p><xref rid="fig7" ref-type="fig">Figures 7A</xref>,<xref rid="fig7" ref-type="fig">B</xref> illustrate that the West Nile virus methyltransferase protein with apigenin ligand has a lower RMSD value compared to the West Nile virus methyltransferase protein with curcumin ligand. In <xref rid="fig7" ref-type="fig">Figures 7A</xref>,<xref rid="fig7" ref-type="fig">B</xref>, Ligand&#x2019;s average RMSD is 0.6785&#x2009;&#x00C5; and 2.066&#x2009;&#x00C5;, respectively. Although the apigenin ligand bound the West Nile virus methyltransferase protein, the low RMSD value showed large fluctuations throughout the simulation. In the case of the ligand curcumin, the fluctuation was just observed during the first 10&#x2009;ns of trajectory. Furthermore, the ligand RMSD stabilized again after 10&#x2009;ns and remained consistent till the end of the simulation time of 100&#x2009;ns. This indicates that the curcumin ligand contacts remained intact during the simulation. According to <xref rid="fig7" ref-type="fig">Figure 7C</xref>, the Ganoderic acid ligand-bound West Nile virus envelope glycoprotein showed a stable RMSD value during the simulation time. The trajectories were analyzed with the VMD program, and the results showed that the ligands curcumin and Ganoderic acid did not jump out of the domain of the protein, indicating that they were located within the binding site. This was discovered when we found that neither of the ligands jumped out of the domain. According to the results of the root-mean-square-difference (RMSD) analysis of the ligands, neither the binding orientation of the curcumin nor the Ganoderic acid ligands changed during the simulation. Apigenin and Ganoderic acid have maintained the same conformational orientation throughout their whole structures and have not deviated from them. This suggests that, in the case of the West Nile virus methyltransferase protein-bound Apigenin-ligand, numerous binding orientations were observed and that this ligand shifted positions throughout MD simulations and departed the binding pocket. The docking position was deemed unacceptable for the candidate with a complex structure. During the 100&#x2009;ns simulation, the RMSD analysis of backbone atoms for the two proteins, West Nile virus methyltransferase and West Nile virus envelope glycoprotein, revealed different conformational states in terms of the protein&#x2019;s backbone. Indeed, curcumin and Ganoderic acid tend to reach a constant equilibrium, but the RMSD of the apigenin backbone was considerably high. The backbone of Apigenin remained distinct throughout the simulation, resulting in a maximum RMSD of 4.5&#x2009;&#x00C5;. This difference in the deviation range explains the change in stability of West Nile virus methyltransferase, which represents the effect of the substituted amino acid on the structure of the protein. The RMSD plots of Apigenin and Curcumin&#x2019;s backbones have average values of 2.91 and 1.76, respectively. The first 30&#x2009;ns of the simulation of curcumin showed instability of the protein, but from 30 to 60&#x2009;ns of simulation, the protein was stable. The first stable conformation of the Ganoderic acid backbone occurs between 20 and 40 nanoseconds, while the second conformation occurs between 60 and 100 nanoseconds. The RMSD remains constant at 1.7&#x2009;&#x00C5;, and between 20&#x2009;ns and 40&#x2009;ns, RMSD &#x003E;5&#x2009;&#x00C5; is observed to fluctuate significantly. Among the three trajectories, the apigenin backbone protein exhibited the greatest variation and the highest RMSD value. As opposed to Apigenin and Curcumin, the Ganoderic acid protein backbone exhibited less divergent patterns. In addition, according to <xref rid="fig7" ref-type="fig">Figure 7</xref>, the average RMSD values for the three complexes were 3.50&#x2009;&#x00C5;, 3.97&#x2009;&#x00C5;, and 5.50&#x2009;&#x00C5;, respectively. As determined by RMSDs, the protein-ligand complex in <xref rid="fig7" ref-type="fig">Figure 7A</xref> exhibited a rising fluctuation, whereas in <xref rid="fig7" ref-type="fig">Figure 7B</xref>, the complex is equilibrated between 50 and 75&#x2009;ns. Also, as can be seen in the complicated <xref rid="fig7" ref-type="fig">Figure 7C</xref>, the trajectory is initially in equilibrium for 5&#x2009;ns, then has a big increase to 16 at 20&#x2009;ns, and finally experiences a substantial reduction to 5.3 at roughly 23&#x2009;ns. From then on, the complex exhibits a wide range of fluctuations, from nearly stable to extremely unstable, until it reaches 70&#x2009;ns. In the last 30&#x2009;ns, the complex has shown persistent, minute fluctuations. As a result, the West Nile virus methyltransferase complex protein-bound apigenin exhibited the lowest RMSD value compared to the curcumin compound and Ganoderic acid compound complexes; however, this did not prove its greater stability and fewer conformational changes compared to other complexes. At the conclusion of the simulation, the ligand appeared highly unstable when complexed with apigenin. The apigenin ligand exhibited substantial variations, indicating the general instability of the complex.</p>
</sec>
<sec id="sec30">
<label>4.4.2.</label>
<title>Root mean square fluctuations</title>
<p>RMSF measures the amount by which atomic locations have deviated from their initial positions and illustrates the dynamic nature of the protein-ligand interaction. In other words, RMSF exemplifies how dynamic the interaction between the protein and the ligand is. As a result, the RMSF data of the protein backbone and complexes were plotted to visualize the average fluctuation of all the amino acid residues, as depicted in <xref rid="fig8" ref-type="fig">Figure 8</xref> for a 100&#x2009;ns MD trajectory. Furthermore, the RMSF value can be used to assess the significance of individual protein residues in preserving the native shape of a protein-ligand complex. A high RMSF number indicates greater flexibility, while a low RMSF value indicates a more stable zone. Hence, a higher number of RMSF residues or groups suggests a higher degree of flexibility, which in turn suggests a higher probability of interaction with ligand molecules. Moreover, reduced RMSF fluctuations are associated with lesser flexibility, resulting in diminished interaction potential. <xref rid="fig8" ref-type="fig">Figure 8A</xref> depicts the RMSF analysis for the ligand apigenin. None of the nine residues with a high RMSF value (RMSF value &#x003E;3) were outside of protein binding sites. In addition, fluctuations of substantial peaks in the RMSF graph were found at LYS45, GLU46, GLY47, ASN48, VAL49, THR50, GLY51, GLY52, and HSD53, which are shown in blue on the protein. Intriguingly, these residues are not part of the binding pocket, and it is hypothesized that they have no significant effect on the ligand-binding process. The curcumin ligand has four different residues that have high RMSF, but none of them are in the protein binding sites. The Ganoderic acid ligand has not exhibited significant fluctuations with low RMSF values, none of which are in protein-binding sites. As demonstrated in <xref rid="fig8" ref-type="fig">Figure 8A</xref>, the RMSF values of the apigenin ligand complex are greater than those of the curcumin structure. The high RMSF values of apigenin indicated a greater degree of flexibility and instability in the protein, whereas the low RMSF values of the curcumin and Ganoderic acid complexes indicated restricted movement of the residues and a rigid structure in the presence of the ligands for West Nile virus methyltransferase. According to the information presented above, the findings of curcumin and Ganoderic acid have demonstrated that, in general, the protein was stable and did not undergo any significant changes. In this investigation, apigenin and protein interactions with RMSF values greater than 2.5 are regarded as having fewer stable bonds. <xref rid="fig8" ref-type="fig">Figure 8</xref>, on the other hand, reveals a negligible distinction between the fluctuation scores of the residues in the protein-curcumin combination and the protein-Ganoderic acid complex. In <xref rid="fig8" ref-type="fig">Figures 8B</xref>,<xref rid="fig8" ref-type="fig">C</xref>, the RMSF plot of ligand-protein for each ligand reveals that the RMSF value at the C-terminal residues (end) is quite high because these residues represent the tails or ends of the protein structure, which are highly reactive and free to move. Each of the two complex system residues, VAL267 (C-terminal), exhibits significantly higher fluctuations than other residues. This is likely because it is placed at the end of the protein chain, allowing it to be more flexible than other residues. In <xref rid="fig8" ref-type="fig">Figure 8C</xref>, the C-terminal residue changed significantly, with RMSF values of 60, whereas for curcumin, it reached 30. <xref rid="fig8" ref-type="fig">Figure 8C</xref> depicts the creation of a highly mobile free-end loop in Ganoderic acid, which may account for the significant variation observed.</p>
<fig position="float" id="fig8">
<label>Figure 8</label>
<caption><p>Derived from a 100&#x2009;ns MD simulation, the RMSF of a complicated protein backbone. The RMSF of the protein backbone is depicted in red. The complex&#x2019;s RMSF is depicted in black. <bold>(A)</bold> <italic>Apigenin</italic> against West Nile virus methyltransferase (PDB ID 2OY0). <bold>(B)</bold> <italic>Curcumin</italic> against West Nile virus methyltransferase (PDB ID 2OY0). <bold>(C)</bold> <italic>Ganoderic acid</italic> against West Nile virus envelope glycoprotein (PDB ID 2169).</p></caption>
<graphic xlink:href="fmicb-14-1189786-g008.tif"/>
</fig>
</sec>
<sec id="sec31">
<label>4.4.3.</label>
<title>Radius of gyration analysis</title>
<p>To evaluate structural compression changes, the gyration radius diagram of each structure was recorded over the course of the simulation. To determine the compactness of the system over time, Rg was calculated, with higher Rg values indicating less compactness (more unfolded) with conformational entropy and lower Rg values indicating high compactness with greater structural stability (more folded). <xref rid="fig9" ref-type="fig">Figure 9</xref> demonstrates that the simulation Rg values for the three complexes are 1 &#x00C5;, 9 &#x00C5;, 1 &#x00C5;, 975 &#x00C5; and 3.5 &#x00C5;, respectively. From the Apigenin plot, it can be seen that the system exhibited little change until 100&#x2009;ns, with the exception of a few unfolding events between 40 and 70&#x2009;ns, after which it stabilized until the end of the simulation. The stability of the protein in the complex was demonstrated by the Rg value, which showed less variation as a result of the fewer changes it experienced. Curcumin, on the other hand, exhibits only very modest fluctuations at the beginning but afterwards demonstrates a significant increase that reaches a Rg value of 2.5 &#x00C5; between 20 and 40&#x2009;ns. In the case of Ganoderic acid, the structure showed a sharp increase of Rg up to 3.75 &#x00C5; at 10&#x2009;ns, then an immediate decrease of the Rg value towards 3.50 &#x00C5;, then an increase towards 3.70 &#x00C5; between 20&#x2009;ns and 40&#x2009;ns, then a gradual fluctuation decreases of Rg towards 3.60 &#x00C5; until the 80&#x2009;ns. At 80&#x2009;ns, there is a sharp decrease in the Rg value towards 3.50 &#x00C5;. After that, an average Rg value of 3.60 A was equilibrated to small fluctuations until the simulation ended. The RG findings demonstrated that the binding of these three molecules induces structural modifications. In general, the patterns of change in RG values across all complexes were distinct. According to the results, the Apigenin complex had the smallest Rg value, which may indicate that it is more compact than the other complexes. A loss of compactness may occur as a consequence of a change in the interaction pattern between the protein and the ligand. The dissolution of hydrogen bonds between molecules might possibly be explained by the curcumin complex&#x2019;s elevated Rg value. It is also possible that conformational changes in the protein structure were induced by the interaction of curcumin with proteins, which dramatically altered the curcumin complex&#x2019;s microenvironment. In addition, the Ganoderic acid complex has been reported to have experienced compositional variations, which indicates a less tightly bound structure.</p>
<fig position="float" id="fig9">
<label>Figure 9</label>
<caption><p>The radius of gyration (Rg) was used to measure and comprehend the compactness of protein complexes and their structure.</p></caption>
<graphic xlink:href="fmicb-14-1189786-g009.tif"/>
</fig>
</sec>
<sec id="sec32">
<label>4.4.4.</label>
<title>Hydrogen bond analysis</title>
<p>It is worthwhile to investigate hydrogen bonding interactions because they contribute to the binding process and, in particular, persistent hydrogen bonds. Using the VMD hydrogen bond analysis tool, all conceivable hydrogen bonding interactions between the two specified areas, in this case the protein and the ligand, have been explored throughout time. Hydrogen bonds are recognized, and the output contains the overall number of hydrogen bonds as well as their occupancy over time. The &#x2018;Percentage occupancy of the Hbond&#x2019; output of the hydrogen bond analysis tool provides access to these values (<xref rid="fig10" ref-type="fig">Figure 10</xref>). In docked complexes, significantly more stable hydrogen bonds are reported to be established. During the Molecular Dynamics (MD) simulations, the H-bonds that were present in the docking structures were not only preserved, but additional H-bonds were also found. Apigenin, curcumin, and Ganoderic acid each have their own individual occupancies of identified H-bonds, which are listed in <xref rid="tab4" ref-type="table">Table 4</xref>.</p>
<fig position="float" id="fig10">
<label>Figure 10</label>
<caption><p>The number of H-bonds formed by the ligand molecule, with the proteins (Apigenin, Curcumin and Ganoderic acid) was obtained from 100&#x2009;ns MD simulation.</p></caption>
<graphic xlink:href="fmicb-14-1189786-g010.tif"/>
</fig>
<table-wrap position="float" id="tab4">
<label>Table 4</label>
<caption><p>Analysis of H-bond occupancies for each ligand during MD simulation.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th/>
<th align="left" valign="top">Donor acceptor</th>
<th align="center" valign="top">Occupancy</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" rowspan="5">Apigenin</td>
<td align="left" valign="top">Apigenin-Side-O3 GLY81-Main-O</td>
<td align="center" valign="top">0.90%</td>
</tr>
<tr>
<td align="left" valign="top">Apigenin-Side-O3 ILE147- Main-O</td>
<td align="center" valign="top">0.10%</td>
</tr>
<tr>
<td align="left" valign="top">LYS105-Main-N Apigenin-Side-O2</td>
<td align="center" valign="top">11.28%</td>
</tr>
<tr>
<td align="left" valign="top">LYS105-Main-N Apigenin-Side-O5</td>
<td align="center" valign="top">3.19%</td>
</tr>
<tr>
<td align="left" valign="top">LYS105-Side-N2 Apigenin-Side-O2</td>
<td align="center" valign="top">10%</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="4">Curcumin</td>
<td align="left" valign="top">Curcumin-Side-O5<break/>ASP131-Side-OD1</td>
<td align="center" valign="top">40%</td>
</tr>
<tr>
<td align="left" valign="top">Curcumin-Side-O3<break/>ASP131-Side-OD2</td>
<td align="center" valign="top">40%</td>
</tr>
<tr>
<td align="left" valign="top">Curcumin-Side-O3<break/>ASP131-Side-OD1</td>
<td align="center" valign="top">1.20%</td>
</tr>
<tr>
<td align="left" valign="top">VAL132-Main-N Curcumin-Side-O3</td>
<td align="center" valign="top">80%</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="5">Ganoderic acid</td>
<td align="left" valign="top">Ganoderic-Side-O7<break/>ILE340-Main-O</td>
<td align="center" valign="top">10%</td>
</tr>
<tr>
<td align="left" valign="top">Ganoderic-Side-O6<break/>ILE340-Main-O</td>
<td align="center" valign="top">19%</td>
</tr>
<tr>
<td align="left" valign="top">Ganoderic-Side-O5<break/>PRO339-Main-O</td>
<td align="center" valign="top">19%</td>
</tr>
<tr>
<td align="left" valign="top">SER341-Side-OG Ganoderic-Side-O4</td>
<td align="center" valign="top">19%</td>
</tr>
<tr>
<td align="left" valign="top">SER341-Side-OG Ganoderic-Side-O5</td>
<td align="center" valign="top">29%</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>In the case of the apigenin complex, during MD, the protein-apigenin complex stability was maintained by interactions with GLY 81, LYS 105, and ILE 147 residues. It has hydrogen bonds with the highest occupancy of 11.28%, where apigenin forms the hydrogen bond with LYS 105. Then 0.90% occupancy, where apigenin plays a role as an acceptor for GLY 81, and 0.10% with ILE 147. Although the Apigenin complex has 50 hydrogen bonds more than the other complexes, the compound (Apigenin) formed only two hydrogen bonds, which were found in docked simulation. Curcumin has 28 total hydrogen bonds, with the highest occupancy of 80%, where curcumin and VAL 132 form hydrogen bonds. Then 40% occupancy, where curcumin plays a role as an acceptor of ASP 131, and 1.20% with ASP 131. Only three of the 28 hydrogen bonds were formed in the docked simulation. We conclude that, during MD, the curcumin complex has more stability than the apigenin complex. Ganoderic acid has 32 total hydrogen bonds with the highest occupancy of 29%, where Ganoderic acid has the role of a donor and SER 341 has the role of an acceptor of hydrogen bond formation. Then 19% occupancy where Fisetin plays a role as an acceptor to ILE 340 and 19% with PRO 339. Only two of the 32 hydrogen bonds were formed in the docked simulation. In the system, hydrogen bonds were stable, and most of them appeared between 0 and 15&#x2009;ns and 40 and 50&#x2009;ns. Hydrogen bond occupancy with a score of more than 100% indicates that more than one atom pair interacts to form hydrogen bonds. Meanwhile, curcumin has a lower total hydrogen bond but a higher hydrogen bond occupancy than Ganoderic acid. This total hydrogen bond and hydrogen bond occupancy determine the stability of each system. The number and occupancy of hydrogen bonds are the keys to the interaction stabilization of the protein-ligand complex.</p>
</sec>
<sec id="sec33">
<label>4.4.5.</label>
<title>Principal component analysis (PCA) and dynamics cross-correlation matrices (DCCM) analysis</title>
<p>Principal component analysis was used to identify and understand significant concerted motions in different regions of the protein. PCA extracts the most variable dynamic motions in simulations, which are required for biological function. In addition, it may be used to examine the effect of various parameters on the collective motion and to reduce the motion&#x2019;s complexity, which is related to the system&#x2019;s stability and protein functions. Also, it can be utilized to characterize the many conformational variations that are associated with the process of protein folding as well as the open-close mechanism of ion channels. The conformational alterations of West Nile virus methyltransferase and West Nile virus envelope glycoprotein were further analyzed using dynamic cross correlation matrix (DCCM) analysis. Principal component analysis (PCA) and a DCCM were used to identify protein backbone conformation shifts. PCA and DCCM were performed using RStudio and Bio3d; axes, each dot represents a different protein configuration. The distribution of blue and red dots represented the extent of conformational changes in the simulation, where the color ranges from blue to white to red corresponds to simulation duration. The color blue represents the initial timestep, the color white represents the intermediate, and the color red represents the final timestep (illustrated in <xref rid="fig11" ref-type="fig">Figure 11</xref>).</p>
<fig position="float" id="fig11">
<label>Figure 11</label>
<caption><p>Principal component analysis of <bold>(A)</bold> Apigenin, <bold>(B)</bold> Curcumin, and <bold>(C)</bold> Ganoderic acid.</p></caption>
<graphic xlink:href="fmicb-14-1189786-g011.tif"/>
</fig>
<p>The first three PCs predicted the majority of the motion of the protein backbone from the MD trajectories in Figure y. In the apigenin protein, PCA analysis shows that the first three eigenvectors account for 47.49, 47.49, and 7.79% (<xref rid="fig12" ref-type="fig">Figure 12A</xref>). In the case of curcumin protein, PCA analysis display that the first three eigenvectors account for 23.79, 23.79, and 6.13% (<xref rid="fig12" ref-type="fig">Figure 12B</xref>). For Ganoderic Acid Protein, PCA analysis display that the first three eigenvectors account for 30.1, 30.1, and 11.34% (<xref rid="fig12" ref-type="fig">Figure 12C</xref>). The highest PC1 (47.49%) was noticed for the apigenin protein, which indicates that the protein had undergone higher conformational changes. The lowest PC1 (6.13%) was observed for the curcumin protein, indicating that the protein had undergone very few conformational changes compared to apigenin. Comparatively, the Ganoderic acid compound exhibited less conformational change than the apigenin complex but more than the curcumin complex.</p>
<fig position="float" id="fig12">
<label>Figure 12</label>
<caption><p>Dynamic cross correlation matrix (DCCM) plots for (Apigenin, Curcumin, and Ganoderic Acid).</p></caption>
<graphic xlink:href="fmicb-14-1189786-g012.tif"/>
</fig>
<p>Additionally, the resulting dynamical cross-correlation graphs exhibit both positive and negative amino acid correlation effects. Overall correlation was displayed by DCCM, and it was in the range of &#x2212;1.0 to 1.0. (From dark purple to dark blue). Various colors were used to denote varying degrees of association between residues, with darker colors indicating stronger correlations. Correlations closer to 1 indicated that the residues were moving in the same direction, while correlations closer to &#x2212;1 indicated that the residues were moving in the opposite direction. In order to see the relationship between the I and J residue indices, we constructed pairwise correlated graphs. Colors such as dark cyan, white, and pink were used to analyze the predicted map results. Fully correlated pairs are denoted by the color cyan, while anti-correlated pairs are denoted by the color pink. Comparative results reveal that the atomic motions in the Apigenin complex resemble more closely those of the Curcumin structure. But, Comparing the DCCM diagrams of the three systems, it could be found that the correlated motions of the apigenin and curcumin systems were noticeably distinct from the Ganoderic complex. We postulate that the simultaneous appearance of positively and negatively correlated movements destabilizes the domain. For this reason, we observed high anti-correlation in the apigenin complex compared to the curcumin complex, indicating a more compact structure of the apigenin. For the Ganoderic acid complex, which showed less anticorrelated and correlated motions and more noncorrelated motions than the Apigenin and Curcumin complexes in all regions of the protein (illustrated in <xref rid="fig12" ref-type="fig">Figure 12</xref>).</p>
</sec>
<sec id="sec34">
<label>4.4.6.</label>
<title>Binding free energy analysis</title>
<p>To analyze the molecular binding interaction of protein-ligand complexes, the binding free energy (G) was calculated using MM-PBSA, which considers both bonded and non-bonded (van der Waals and electrostatic) interactions. Using MMPBSA and the final 20&#x2009;ns of the trajectory, the binding free energies of the protein-ligand complexes were calculated. Using the MMGBSA approach, the binding free energy (&#x2206; Gbind) of 12 natural compounds, of which top nine were chosen based on binding affinity score, was determined. The greater the negative values, the more favorable the binding free energy between proteins and ligands. As shown in <xref rid="tab4" ref-type="table">Table 4</xref> and <xref rid="fig13" ref-type="fig">Figure 13</xref>, the free binding energies of the natural compounds agree with the molecular docking results. The Hesperetin, Lucidone, and Cholic acid demonstrated the greatest amount of binding energy (&#x2212;16.44&#x2009;kcal/mol, &#x2212;19.78&#x2009;kcal/mol and&#x2009;&#x2212;&#x2009;29.00) in comparison to the other natural chemicals. This energy is mostly different from the curcumin compound, and it means that the interaction in the compound Hesperetin, Lucidone, and Cholic acid complex is the most stable interaction during simulation, followed by the protein-compound complex. On the other hand, the compound Ganoderic acid complex has the most positive binding energy, indicating that the interaction between compound Ganoderic acid and the target protein active site is the weakest.</p>
<fig position="float" id="fig13">
<label>Figure 13</label>
<caption><p>Binding free energy plot.</p></caption>
<graphic xlink:href="fmicb-14-1189786-g013.tif"/>
</fig>
<p><xref rid="tab5" ref-type="table">Table 5</xref> and <xref rid="fig13" ref-type="fig">Figure 13</xref> highlights the primary components of binding free energy for protein-ligand complexes, including van der Waals (&#x0394;EVDW), electrostatics (&#x0394;EEEL), a polar portion of solvation (&#x0394;GPB), non-polar part of solvation (&#x0394;GNP), dispersion (&#x0394;GDISP), and binding energy (&#x0394;G).</p>
<table-wrap position="float" id="tab5">
<label>Table 5</label>
<caption><p>Binding energy results.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th colspan="2"/>
<th align="center" valign="top">&#x0394;EVDW (kJ/mol)</th>
<th align="center" valign="top">&#x0394;EEEL<break/>(kJ/mol)</th>
<th align="center" valign="top">&#x0394;GPB<break/>(kJ/mol)</th>
<th align="center" valign="top">&#x0394;GNP<break/>(kJ/mol)</th>
<th align="center" valign="top">&#x0394;GDISP<break/>(kJ/mol)</th>
<th align="center" valign="top">&#x0394;G Binding<break/>(kJ/mol)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">01</td>
<td align="left" valign="top">Apigenin</td>
<td align="center" valign="top">&#x2212;21.76</td>
<td align="center" valign="top">&#x2212;8.06</td>
<td align="center" valign="top">21.93</td>
<td align="center" valign="top">&#x2212;2.98</td>
<td align="center" valign="top">0.0</td>
<td align="center" valign="top">&#x2212;10.88</td>
</tr>
<tr>
<td align="left" valign="middle">02</td>
<td align="left" valign="middle">Resveratrol</td>
<td align="center" valign="top">&#x2212;21.27</td>
<td align="center" valign="top">&#x2212;19.65</td>
<td align="center" valign="top">32.80</td>
<td align="center" valign="top">&#x2212;2.93</td>
<td align="center" valign="top">0.0</td>
<td align="center" valign="top">&#x2212;11.05</td>
</tr>
<tr>
<td align="left" valign="middle">03</td>
<td align="left" valign="top">Hesperetin</td>
<td align="center" valign="top">&#x2212;25.87</td>
<td align="center" valign="top">&#x2212;8.51</td>
<td align="center" valign="top">21.13</td>
<td align="center" valign="top">&#x2212;3.19</td>
<td align="center" valign="top">0.0</td>
<td align="center" valign="top">&#x2212;16.44</td>
</tr>
<tr>
<td align="left" valign="middle">05</td>
<td align="left" valign="top">Lucidone</td>
<td align="center" valign="top">&#x2212;25.46</td>
<td align="center" valign="top">&#x2212;16.61</td>
<td align="center" valign="top">25.38</td>
<td align="center" valign="top">&#x2212;3.09</td>
<td align="center" valign="top">0.0</td>
<td align="center" valign="top">&#x2212;19.78</td>
</tr>
<tr>
<td align="left" valign="middle">06</td>
<td align="left" valign="middle">Ganoderic acid</td>
<td align="center" valign="top">&#x2212;0.00</td>
<td align="center" valign="top">0.00</td>
<td align="center" valign="top">3.05</td>
<td align="center" valign="top">&#x2212;0.06</td>
<td align="center" valign="top">0.0</td>
<td align="center" valign="top">2.99</td>
</tr>
<tr>
<td align="left" valign="middle">07</td>
<td align="left" valign="top">Curcumin</td>
<td align="center" valign="top">&#x2212;0.00</td>
<td align="center" valign="top">&#x2212;1.43</td>
<td align="center" valign="top">6.26</td>
<td align="center" valign="top">&#x2212;0.80</td>
<td align="center" valign="top">0.0</td>
<td align="center" valign="top">&#x2212;0.05</td>
</tr>
<tr>
<td align="left" valign="middle">08</td>
<td align="left" valign="top">Kaempferol</td>
<td align="center" valign="top">&#x2212;22.78</td>
<td align="center" valign="top">&#x2212;16.56</td>
<td align="center" valign="top">29.34</td>
<td align="center" valign="top">&#x2212;3.14</td>
<td align="center" valign="top">0.0</td>
<td align="center" valign="top">&#x2212;13.15</td>
</tr>
<tr>
<td align="left" valign="middle">09</td>
<td align="left" valign="top">Cholic acid</td>
<td align="center" valign="top">&#x2212;15.82</td>
<td align="center" valign="top">&#x2212;277.93</td>
<td align="center" valign="top">267.47</td>
<td align="center" valign="top">&#x2212;2.72</td>
<td align="center" valign="top">0.0</td>
<td align="center" valign="top">&#x2212;29.00</td>
</tr>
<tr>
<td align="left" valign="middle">10</td>
<td align="left" valign="top">Chlorogenic acid</td>
<td align="center" valign="top">&#x2212;33.86</td>
<td align="center" valign="top">&#x2212;38.33</td>
<td align="center" valign="top">69.52</td>
<td align="center" valign="top">&#x2212;4.03</td>
<td align="center" valign="top">0.0</td>
<td align="center" valign="top">&#x2212;6.71</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
</sec>
<sec id="sec35">
<label>4.5.</label>
<title>ADME, aquatic and non-aquatic toxicity</title>
<p>By utilizing the pkCSM web server, ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties were performed. The <xref rid="tab6" ref-type="table">Table 6</xref> displays the reported compound&#x2019;s ADMET values. Drug development fails in between 40 and 60% of cases as a result of inadequate ADMET characteristics. The virtual screening process should take this pharmacokinetics characteristic into consideration as a major factor. The range of the water solubility log S has been reported &#x2212;2.449 to &#x2212;6.618. All compounds had significant levels of intestinal absorption in humans excluding 10. The VDss level varies from &#x2212;2.172 to 0.822, with a maximum Total Clearance rate of 0.653&#x2009;mL/min/kg. 4,5,6,11 and 12 number compounds have the permeability to the Blood&#x2013;brain barrier 1,2,3,7,8,9and 10 compounds cannot pass the Blood&#x2013;brain barrier. The CYP450 A2 substrate can be inhibited by most of the compounds. The CYP450 2C9 substrate can only be inhibited by 12 specific drugs; other compounds are inactive. Both of these enzymes are crucial for the metabolism of drugs and are frequently present in the human liver. In the disposition and renal clearance of mostly cationic drug molecules, renal OCT2 substrate in the kidney plays a very significant function. Finally, they all are free from AMES toxicity, Skin Sensitization and Hepatotoxicity (<xref rid="tab6" ref-type="table">Table 6</xref>).</p>
<table-wrap position="float" id="tab6">
<label>Table 6</label>
<caption><p>Summary of <italic>in silico</italic> ADMET prediction.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top" rowspan="2">S/N</th>
<th align="center" valign="top" colspan="3">Absorption</th>
<th align="center" valign="top" colspan="2">Distribution</th>
<th align="center" valign="top" colspan="2">Metabolism</th>
<th align="center" valign="top" colspan="2">Excretion</th>
<th align="center" valign="top" colspan="3">Toxicity</th>
</tr>
<tr>
<th align="center" valign="bottom">Water solubility<break/>Log S</th>
<th align="center" valign="bottom">Caco-2<break/>Permeability &#x00D7; 10<sup>&#x2212;6</sup></th>
<th align="center" valign="bottom">Human Intestinal Absorption (%)</th>
<th align="center" valign="bottom">VDss (human)</th>
<th align="center" valign="bottom">BBB<break/>Permeability</th>
<th align="center" valign="bottom">CYP450 1A2<break/>Inhibitor</th>
<th align="center" valign="bottom">CYP450 2C9<break/>Substrate</th>
<th align="center" valign="bottom">Total Clearance (ml/min/kg)</th>
<th align="center" valign="bottom">Renal OCT2<break/>substrate</th>
<th align="center" valign="bottom">AMES toxicity</th>
<th align="center" valign="bottom">Skin Sensitization</th>
<th align="center" valign="bottom">Hepatotoxicity</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">01</td>
<td align="center" valign="middle">&#x2212;3.329</td>
<td align="center" valign="middle">1.007</td>
<td align="center" valign="middle">93.25</td>
<td align="center" valign="middle">0.822</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">Yes</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">0.566</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="top">No</td>
<td align="center" valign="top">No</td>
<td align="center" valign="top">No</td>
</tr>
<tr>
<td align="left" valign="middle">02</td>
<td align="center" valign="middle">&#x2212;3.178</td>
<td align="center" valign="middle">1.17</td>
<td align="center" valign="middle">90.935</td>
<td align="center" valign="middle">0.296</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">Yes</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">0.076</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">Yes</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">No</td>
</tr>
<tr>
<td align="left" valign="middle">03</td>
<td align="center" valign="middle">&#x2212;3.407</td>
<td align="center" valign="middle">0.294</td>
<td align="center" valign="middle">70.277</td>
<td align="center" valign="middle">0.746</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">0.444</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">No</td>
</tr>
<tr>
<td align="left" valign="middle">04</td>
<td align="center" valign="middle">&#x2212;6.818</td>
<td align="center" valign="middle">1.205</td>
<td align="center" valign="middle">94.757</td>
<td align="center" valign="middle">0.29</td>
<td align="center" valign="middle">Yes</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">0.565</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">No</td>
</tr>
<tr>
<td align="left" valign="middle">05</td>
<td align="center" valign="middle">&#x2212;2.701</td>
<td align="center" valign="middle">1.144</td>
<td align="center" valign="middle">95.474</td>
<td align="center" valign="middle">&#x2212;0.125</td>
<td align="center" valign="middle">Yes</td>
<td align="center" valign="middle">Yes</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">0.11</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">Yes</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">No</td>
</tr>
<tr>
<td align="left" valign="middle">06</td>
<td align="center" valign="middle">&#x2212;3.058</td>
<td align="center" valign="middle">2.625</td>
<td align="center" valign="middle">66.348</td>
<td align="center" valign="middle">&#x2212;2.172</td>
<td align="center" valign="middle">Yes</td>
<td align="center" valign="middle">Yes</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">&#x2212;0.369</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">Yes</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">No</td>
</tr>
<tr>
<td align="left" valign="middle">07</td>
<td align="center" valign="middle">&#x2212;2.892</td>
<td align="center" valign="middle">1.643</td>
<td align="center" valign="middle">78.45</td>
<td align="center" valign="middle">0.011</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">Yes</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">&#x2212;57.293</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">Yes</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">No</td>
</tr>
<tr>
<td align="left" valign="middle">08</td>
<td align="center" valign="middle">&#x2212;3.04</td>
<td align="center" valign="middle">0.032</td>
<td align="center" valign="middle">74.29</td>
<td align="center" valign="middle">1.274</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">Yes</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">0.477</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">No</td>
</tr>
<tr>
<td align="left" valign="middle">09</td>
<td align="center" valign="middle">&#x2212;3.763</td>
<td align="center" valign="middle">0.597</td>
<td align="center" valign="middle">61.546</td>
<td align="center" valign="middle">&#x2212;0.804</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">0.653</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">No</td>
</tr>
<tr>
<td align="left" valign="middle">10</td>
<td align="center" valign="middle">&#x2212;2.449</td>
<td align="center" valign="middle">&#x2212;0.84</td>
<td align="center" valign="middle">36.377</td>
<td align="center" valign="middle">0.581</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">0.307</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="top">No</td>
<td align="center" valign="top">No</td>
<td align="center" valign="top">No</td>
</tr>
<tr>
<td align="left" valign="middle">11</td>
<td align="center" valign="middle">&#x2212;3.538</td>
<td align="center" valign="middle">1.152</td>
<td align="center" valign="middle">92.417</td>
<td align="center" valign="middle">&#x2212;0.386</td>
<td align="center" valign="middle">Yes</td>
<td align="center" valign="middle">Yes</td>
<td align="center" valign="middle">Yes</td>
<td align="center" valign="middle">0.122</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">No</td>
</tr>
<tr>
<td align="left" valign="middle">12</td>
<td align="center" valign="middle">&#x2212;2.892</td>
<td align="center" valign="middle">0.239</td>
<td align="center" valign="middle">82.294</td>
<td align="center" valign="middle">0.011</td>
<td align="center" valign="middle">Yes</td>
<td align="center" valign="middle">Yes</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">&#x2212;0.416</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">Yes</td>
<td align="center" valign="middle">No</td>
<td align="center" valign="middle">No</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
</sec>
<sec id="sec36" sec-type="conclusions">
<label>5.</label>
<title>Conclusion</title>
<p>Our <italic>in-silico</italic> research has been reported that all the natural molecules have better binding affinity, high solubility in aqueous system, free from hepatic toxicity, and skin sensitization, most of them are accepted by lipinski rule. Besides, different types of active amino acid are seen during the formation of drug protein complexes such as VAL-A:132, ASP-A:131, PHE-A:133, LYS-A:105, ASP-A:146, TRP-A:87, GLY-A:58, ASP. The most active compounds were reported Apigenin against <italic>West Nile virus methyltransferase (PDB ID 2OY0), and</italic> Fungisterol, &#x0026; Sanguinarine against <italic>West Nile virus envelope glycoprotein (PDB ID 2I69) with maximum binding affinity&#x2009;&#x2212;&#x2009;8.1.3&#x2009;kcal/mol, and&#x2009;&#x2212;&#x2009;8.1&#x2009;kcal/mol</italic>. The drug-likeness properties, and the theoretical ADMET data is accepted by our reported phytocompounds. After that, their stability is confirmed by molecular dynamic simulation at 100&#x2009;ns which is also confirmed that the molecules are highly stable when form protein ligands complex<italic>. As, t</italic>here is currently neither an antiviral medicine nor a vaccination that can treat WNV infection in people. In the course of drug discovery and repurposed research, various potential natural molecules have been studied in this investigation that capable to inhibit WNV <italic>in silico</italic> model; however, none of these candidates have performed it to the stage of clinical assessment. Now, further experimental studies should be conducted and determine their practical value to establish them as potential drug candidate for further use.</p>
</sec>
<sec id="sec40" sec-type="data-availability">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.</p>
</sec>
<sec id="sec37">
<title>Author contributions</title>
<p>SA, IB, MR, NM, SM, MI, SR, AG, SA-H, MZ, VJ, SS, JB, and RS: data collection, conceptualization, methodology, software, validation, formal analysis, investigation, resources, data curation, writing&#x2014;original draft preparation, writing&#x2014;review and editing, visualization, supervision, project administration, and funding acquisition. All authors contributed to the article and approved the submitted version.</p>
</sec>
<sec id="sec38" sec-type="funding-information">
<title>Funding</title>
<p>This research was supported by the Deanship of Scientific Research, Imam Mohammad Ibn Saud Islamic University (IMSIU), Saudi Arabia.</p>
</sec>
<sec id="conf1" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="sec100" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="ref1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abba</surname> <given-names>Y.</given-names></name> <name><surname>Hassim</surname> <given-names>H.</given-names></name> <name><surname>Hamzah</surname> <given-names>H.</given-names></name> <name><surname>Noordin</surname> <given-names>M. M.</given-names></name></person-group> (<year>2015</year>). <article-title>Antiviral activity of resveratrol against human and animal viruses</article-title>. <source>Adv. Virol.</source> <volume>2015</volume>, <fpage>1</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1155/2015/184241</pub-id></citation></ref>
<ref id="ref2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname> <given-names>S.</given-names></name> <name><surname>Mehrotra</surname> <given-names>R.</given-names></name></person-group> (<year>2016</year>). <article-title>An overview of molecular docking</article-title>. <source>JSM Chem.</source> <volume>4</volume>, <fpage>1024</fpage>&#x2013;<lpage>1028</lpage>.</citation></ref>
<ref id="ref3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agrawal</surname> <given-names>P. K.</given-names></name> <name><surname>Agrawal</surname> <given-names>C.</given-names></name> <name><surname>Blunden</surname> <given-names>G.</given-names></name></person-group> (<year>2021</year>). <article-title>Pharmacological significance of hesperidin and hesperetin, two citrus flavonoids, as promising antiviral compounds for prophylaxis against and combating COVID-19</article-title>. <source>Nat. Prod. Commun.</source> <volume>16</volume>. doi: <pub-id pub-id-type="doi">10.1177/1934578X211042540</pub-id></citation></ref>
<ref id="ref4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>AI Azzam</surname> <given-names>K.</given-names></name></person-group> (<year>2023</year>). <article-title>SwissADME and pkCSM webservers predictors: an integrated online platform for accurate and comprehensive predictions for in silico ADME/T properties of artemisinin and its derivatives</article-title>. <source>Eng. Technol.</source> <volume>325</volume>, <fpage>14</fpage>&#x2013;<lpage>21</lpage>. doi: <pub-id pub-id-type="doi">10.31643/2023/6445.13</pub-id></citation></ref>
<ref id="ref5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aini</surname> <given-names>N. S.</given-names></name> <name><surname>Kharisma</surname> <given-names>V. D.</given-names></name> <name><surname>Widyananda</surname> <given-names>M. H.</given-names></name> <name><surname>Murtadlo</surname> <given-names>A. A. A.</given-names></name> <name><surname>Probojati</surname> <given-names>R. T.</given-names></name> <name><surname>Turista</surname> <given-names>D. D. R.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>In silico screening of bioactive compounds from <italic>Syzygium cumini</italic> L. and <italic>moringa oleifera</italic> L. against SARS-CoV-2 via tetra inhibitors</article-title>. <source>Pharm. J.</source> <volume>14</volume>, <fpage>267</fpage>&#x2013;<lpage>272</lpage>. doi: <pub-id pub-id-type="doi">10.5530/pj.2022.14.95</pub-id></citation></ref>
<ref id="ref6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akash</surname> <given-names>S.</given-names></name></person-group> (<year>2022</year>). <article-title>Computational screening of novel therapeutic and potent molecules from bioactive trehalose and it&#x2019;s eight derivatives by different insilico studies for the treatment of diabetes mellitus</article-title>. <source>Organic Commun.</source> <volume>15</volume>, <fpage>288</fpage>&#x2013;<lpage>296</lpage>. doi: <pub-id pub-id-type="doi">10.25135/acg.oc.134.2204.2446</pub-id></citation></ref>
<ref id="ref7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akash</surname> <given-names>S.</given-names></name> <name><surname>Kumer</surname> <given-names>A.</given-names></name> <name><surname>Chandro</surname> <given-names>A.</given-names></name> <name><surname>Chakma</surname> <given-names>U.</given-names></name> <name><surname>Matin</surname> <given-names>M. M.</given-names></name></person-group> (<year>2022</year>). <article-title>Quantum calculation, docking, ADMET and molecular dynamics of ketal and non-ketal forms of D-glucofuranose against bacteria, black &#x0026; white fungus, and triple-negative breast cancer</article-title>. <source>Biointerface Res. Appl. Chem.</source> <volume>13</volume>:<fpage>374</fpage>.</citation></ref>
<ref id="ref8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baba</surname> <given-names>M.</given-names></name> <name><surname>Schols</surname> <given-names>D.</given-names></name> <name><surname>Nakashima</surname> <given-names>H.</given-names></name> <name><surname>Pauwels</surname> <given-names>R.</given-names></name> <name><surname>Parmentier</surname> <given-names>G.</given-names></name> <name><surname>Meijer</surname> <given-names>D. K.</given-names></name> <etal/></person-group>. (<year>1989</year>). <article-title>Selective activity of several cholic acid derivatives against human immunodeficiency virus replication in vitro</article-title>. <volume>2</volume>, <fpage>264</fpage>&#x2013;<lpage>271</lpage>.</citation></ref>
<ref id="ref9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bergmann</surname> <given-names>F.</given-names></name> <name><surname>Trachsel</surname> <given-names>D. S.</given-names></name> <name><surname>Stoeckle</surname> <given-names>S. D.</given-names></name> <name><surname>Bernis Sierra</surname> <given-names>J.</given-names></name> <name><surname>L&#x00FC;bke</surname> <given-names>S.</given-names></name> <name><surname>Groschup</surname> <given-names>M. H.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Seroepidemiological survey of West Nile virus infections in horses from Berlin/Brandenburg and North Rhine-Westphalia, Germany</article-title>. <source>Viruses</source> <volume>14</volume>:<fpage>243</fpage>. doi: <pub-id pub-id-type="doi">10.3390/v14020243</pub-id>, PMID: <pub-id pub-id-type="pmid">35215837</pub-id></citation></ref>
<ref id="ref10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boh</surname> <given-names>B.</given-names></name> <name><surname>Berovic</surname> <given-names>M.</given-names></name> <name><surname>Zhang</surname> <given-names>J.</given-names></name> <name><surname>Zhi-Bin</surname> <given-names>L.</given-names></name></person-group> (<year>2007</year>). <article-title>Ganoderma lucidum and its pharmaceutically active compounds</article-title>. <source>Biotechnol. Annu. Rev.</source> <volume>13</volume>, <fpage>265</fpage>&#x2013;<lpage>301</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1387-2656(07)13010-6</pub-id></citation></ref>
<ref id="ref11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burley</surname> <given-names>S. K.</given-names></name> <name><surname>Berman</surname> <given-names>H. M.</given-names></name> <name><surname>Kleywegt</surname> <given-names>G. J.</given-names></name> <name><surname>Markley</surname> <given-names>J. L.</given-names></name> <name><surname>Nakamura</surname> <given-names>H.</given-names></name> <name><surname>Velankar</surname> <given-names>S. J. P. C.</given-names></name></person-group> (<year>2017</year>). <article-title>Protein Data Bank (PDB): the single global macromolecular structure archive</article-title>. <source>Methods Mol. Biol.</source>, <fpage>627</fpage>&#x2013;<lpage>641</lpage>. doi: <pub-id pub-id-type="doi">10.1007/978-1-4939-7000-1_26</pub-id></citation></ref>
<ref id="ref12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Campagna</surname> <given-names>M.</given-names></name> <name><surname>Rivas</surname> <given-names>C.</given-names></name></person-group> (<year>2010</year>). <article-title>Antiviral activity of resveratrol</article-title>. <source>Biochem. Soc. Trans.</source> <volume>38</volume>, <fpage>50</fpage>&#x2013;<lpage>53</lpage>. doi: <pub-id pub-id-type="doi">10.1042/BST0380050</pub-id></citation></ref>
<ref id="ref13"><citation citation-type="web"><person-group person-group-type="author"><collab id="coll1">CDC</collab></person-group>. (<year>n.d.</year>). Treatment &#x0026; Prevention. Available at: <ext-link xlink:href="https://www.cdc.gov/westnile/healthcareproviders/healthCareProviders-TreatmentPrevention.html" ext-link-type="uri">https://www.cdc.gov/westnile/healthcareproviders/healthCareProviders-TreatmentPrevention.html</ext-link> (Accessed November 9, 2021).</citation></ref>
<ref id="ref14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>W.-C.</given-names></name> <name><surname>Tseng</surname> <given-names>C.-K.</given-names></name> <name><surname>Lin</surname> <given-names>C.-K.</given-names></name> <name><surname>Wang</surname> <given-names>S.-N.</given-names></name> <name><surname>Wang</surname> <given-names>W.-H.</given-names></name> <name><surname>Hsu</surname> <given-names>S.-H.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Lucidone suppresses dengue viral replication through the induction of heme oxygenase-1</article-title>. <source>Virulence</source> <volume>9</volume>, <fpage>588</fpage>&#x2013;<lpage>603</lpage>. doi: <pub-id pub-id-type="doi">10.1080/21505594.2017.1421893</pub-id>, PMID: <pub-id pub-id-type="pmid">29338543</pub-id></citation></ref>
<ref id="ref15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>W.-C.</given-names></name> <name><surname>Wang</surname> <given-names>S.-Y.</given-names></name> <name><surname>Chiu</surname> <given-names>C.-C.</given-names></name> <name><surname>Tseng</surname> <given-names>C.-K.</given-names></name> <name><surname>Lin</surname> <given-names>C.-K.</given-names></name> <name><surname>Wang</surname> <given-names>H.-C.</given-names></name> <etal/></person-group>. (<year>2013</year>). <article-title>Lucidone suppresses hepatitis C virus replication by Nrf2-mediated heme oxygenase-1 induction</article-title>. <source>Antimicrob. Agents Chemother.</source> <volume>57</volume>, <fpage>1180</fpage>&#x2013;<lpage>1191</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.02053-12</pub-id>, PMID: <pub-id pub-id-type="pmid">23254429</pub-id></citation></ref>
<ref id="ref16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Daina</surname> <given-names>A.</given-names></name> <name><surname>Michielin</surname> <given-names>O.</given-names></name> <name><surname>Zoete</surname> <given-names>V.</given-names></name></person-group> (<year>2017</year>). <article-title>SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules</article-title>. <source>Sci. Rep.</source> <volume>7</volume>:<fpage>42717</fpage>. doi: <pub-id pub-id-type="doi">10.1038/srep42717</pub-id>, PMID: <pub-id pub-id-type="pmid">28256516</pub-id></citation></ref>
<ref id="ref17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname> <given-names>Y.</given-names></name> <name><surname>Cao</surname> <given-names>Z.</given-names></name> <name><surname>Cao</surname> <given-names>L.</given-names></name> <name><surname>Ding</surname> <given-names>G.</given-names></name> <name><surname>Wang</surname> <given-names>Z.</given-names></name> <name><surname>Xiao</surname> <given-names>W.</given-names></name></person-group> (<year>2017</year>). <article-title>Antiviral activity of chlorogenic acid against influenza a (H1N1/H3N2) virus and its inhibition of neuraminidase</article-title>. <source>Sci. Rep.</source> <volume>7</volume>:<fpage>45723</fpage>. doi: <pub-id pub-id-type="doi">10.1038/srep45723</pub-id></citation></ref>
<ref id="ref18"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Fahmi</surname> <given-names>M.</given-names></name> <name><surname>Kharisma</surname> <given-names>V. D.</given-names></name> <name><surname>Ansori</surname> <given-names>A. N. M.</given-names></name> <name><surname>Ito</surname> <given-names>M.</given-names></name></person-group> (<year>2021</year>). &#x201C;<article-title>Retrieval and investigation of data on SARS-CoV-2 and COVID-19 using bioinformatics approach</article-title>&#x201D; in <source>Coronavirus disease-COVID-19</source> (<publisher-loc>Cham</publisher-loc>: <publisher-name>Springer</publisher-name>), <fpage>839</fpage>&#x2013;<lpage>857</lpage>.</citation></ref>
<ref id="ref19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Farahat</surname> <given-names>R. A.</given-names></name> <name><surname>Memish</surname> <given-names>Z. A.</given-names></name></person-group> (<year>2022</year>). <article-title>Re-emergence of Marburg virus and monkeypox in the shadow of COVID-19 pandemic: current situation and implications&#x2013;correspondence</article-title>. <source>Int. J. Surg.</source> <volume>106</volume>:<fpage>106923</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijsu.2022.106923</pub-id>, PMID: <pub-id pub-id-type="pmid">36122837</pub-id></citation></ref>
<ref id="ref20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feldman</surname> <given-names>N.</given-names></name> <name><surname>Kuryakov</surname> <given-names>V.</given-names></name> <name><surname>Sedyakina</surname> <given-names>N.</given-names></name> <name><surname>Gromovykh</surname> <given-names>T.</given-names></name> <name><surname>Lutsenko</surname> <given-names>S. V.</given-names></name></person-group> (<year>2018</year>). <article-title>Preparation of liposomes containing benzophenanthridine alkaloid sanguinarine and evaluation of its cytotoxic activity</article-title>. <source>Int. J. Nanotechnol.</source> <volume>15</volume>, <fpage>280</fpage>&#x2013;<lpage>287</lpage>.</citation></ref>
<ref id="ref21"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Ghildiyal</surname> <given-names>R.</given-names></name> <name><surname>Prakash</surname> <given-names>V.</given-names></name> <name><surname>Chaudhary</surname> <given-names>V.</given-names></name> <name><surname>Gupta</surname> <given-names>V.</given-names></name> <name><surname>Gabrani</surname> <given-names>R.</given-names></name></person-group> (<year>2020</year>). &#x201C;<article-title>Phytochemicals as antiviral agents: recent updates</article-title>&#x201D; in <source>Plant-derived bioactives</source> (<publisher-loc>New York, NY</publisher-loc>: <publisher-name>Springer</publisher-name>), <fpage>279</fpage>&#x2013;<lpage>295</lpage>.</citation></ref>
<ref id="ref22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname> <given-names>W.-D.</given-names></name> <name><surname>Yang</surname> <given-names>Z.-F.</given-names></name> <name><surname>Liu</surname> <given-names>N.</given-names></name> <name><surname>Qin</surname> <given-names>S.</given-names></name> <name><surname>Zhang</surname> <given-names>F.-X.</given-names></name> <name><surname>Zhu</surname> <given-names>Y.-T.</given-names></name></person-group> (<year>2008</year>). <article-title>In vitro experimental study on the effect of resveratrol against several kinds of respiroviruses</article-title>. <source>Zhong Yao Cai</source> <volume>31</volume>, <fpage>1388</fpage>&#x2013;<lpage>1390</lpage>.</citation></ref>
<ref id="ref23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guang</surname> <given-names>H.-M.</given-names></name> <name><surname>Du</surname> <given-names>G.-H.</given-names></name></person-group> (<year>2006</year>). <article-title>Protections of pinocembrin on brain mitochondria contribute to cognitive improvement in chronic cerebral hypoperfused rats</article-title>. <source>Eur. J. Pharmacol.</source> <volume>542</volume>, <fpage>77</fpage>&#x2013;<lpage>83</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ejphar.2006.04.054</pub-id></citation></ref>
<ref id="ref24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Han</surname> <given-names>J.-Y.</given-names></name> <name><surname>Jeong</surname> <given-names>H. I.</given-names></name> <name><surname>Park</surname> <given-names>C.-W.</given-names></name> <name><surname>Yoon</surname> <given-names>J.</given-names></name> <name><surname>Ko</surname> <given-names>J.</given-names></name> <name><surname>Nam</surname> <given-names>S.-J.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Cholic acid attenuates ER stress-induced cell death in Coxsackievirus-B3 infection</article-title>. <source>J. Microbiol. Biotechnol.</source> <volume>28</volume>, <fpage>109</fpage>&#x2013;<lpage>114</lpage>. doi: <pub-id pub-id-type="doi">10.4014/jmb.1708.08009</pub-id>, PMID: <pub-id pub-id-type="pmid">29032641</pub-id></citation></ref>
<ref id="ref25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hayes</surname> <given-names>C. G.</given-names></name></person-group> (<year>2001</year>). <article-title>West Nile virus: Uganda, 1937, to New York City, 1999</article-title>. <source>Ann. N. Y. Acad. Sci.</source> <volume>951</volume>, <fpage>25</fpage>&#x2013;<lpage>37</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1749-6632.2001.tb02682.x</pub-id>, PMID: <pub-id pub-id-type="pmid">11797781</pub-id></citation></ref>
<ref id="ref26"><citation citation-type="web"><article-title>West Nile Virus Found in Another NY County, Bringing Case Total to 5</article-title>. (<year>n.d.</year>). <comment>Available at:</comment> <ext-link xlink:href="https://www.nbcnewyork.com/news/local/west-nile-virus-found-in-another-ny-county-bringing-state-case-total-to-5/3858809/" ext-link-type="uri">https://www.nbcnewyork.com/news/local/west-nile-virus-found-in-another-ny-county-bringing-state-case-total-to-5/3858809/</ext-link></citation></ref>
<ref id="ref27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname> <given-names>K.-K.</given-names></name> <name><surname>Lin</surname> <given-names>M.-N.</given-names></name> <name><surname>Hsu</surname> <given-names>H.-C.</given-names></name> <name><surname>Hsu</surname> <given-names>Y.-L.</given-names></name> <name><surname>Huang</surname> <given-names>T.-N.</given-names></name> <name><surname>Lu</surname> <given-names>I.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Pinocembrin reduces keratinocyte activation and ameliorates imiquimod-induced psoriasis-like dermatitis in BALB/c mice through the Heme Oxygenase-1/signal transducer and activator of transcription 3 pathway</article-title>. <source>Evid. Based Complement. Alternat. Med.</source> <volume>2022</volume>, <volume>2022</volume>:<fpage>7729836</fpage>. doi: <pub-id pub-id-type="doi">10.1155/2022/7729836</pub-id></citation></ref>
<ref id="ref28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kanai</surname> <given-names>R.</given-names></name> <name><surname>Kar</surname> <given-names>K.</given-names></name> <name><surname>Anthony</surname> <given-names>K.</given-names></name> <name><surname>Gould</surname> <given-names>L. H.</given-names></name> <name><surname>Ledizet</surname> <given-names>M.</given-names></name> <name><surname>Fikrig</surname> <given-names>E.</given-names></name> <etal/></person-group>. (<year>2006</year>). <article-title>Crystal structure of West Nile virus envelope glycoprotein reveals viral surface epitopes</article-title>. <source>J. Virol.</source> <volume>80</volume>, <fpage>11000</fpage>&#x2013;<lpage>11008</lpage>. doi: <pub-id pub-id-type="doi">10.1128/JVI.01735-06</pub-id>, PMID: <pub-id pub-id-type="pmid">16943291</pub-id></citation></ref>
<ref id="ref29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kawsar</surname> <given-names>S.</given-names></name> <name><surname>Kumer</surname> <given-names>A.</given-names></name> <name><surname>Munia</surname> <given-names>N. S.</given-names></name> <name><surname>Hosen</surname> <given-names>M. A.</given-names></name> <name><surname>Chakma</surname> <given-names>U.</given-names></name> <name><surname>Akash</surname> <given-names>S. J. O. C.</given-names></name></person-group> (<year>2022</year>). <article-title>Chemical descriptors, PASS, molecular docking, molecular dynamics and ADMET predictions of glucopyranoside derivatives as inhibitors to bacteria and fungi growth</article-title>. <source>Organ. Communicat.</source> <volume>15</volume>, <fpage>184</fpage>&#x2013;<lpage>203</lpage>. doi: <pub-id pub-id-type="doi">10.25135/acg.oc.122.2203.2397</pub-id></citation></ref>
<ref id="ref30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kemmerly</surname> <given-names>S. A.</given-names></name></person-group> (<year>2003</year>). <article-title>Diagnosis and treatment of West Nile infections</article-title>. <source>Ochsner J.</source> <volume>5</volume>, <fpage>16</fpage>&#x2013;<lpage>17</lpage>. PMID: <pub-id pub-id-type="pmid">21765764</pub-id></citation></ref>
<ref id="ref31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khazdair</surname> <given-names>M. R.</given-names></name> <name><surname>Anaeigoudari</surname> <given-names>A.</given-names></name> <name><surname>Agbor</surname> <given-names>G. A.</given-names></name></person-group> (<year>2021</year>). <article-title>Anti-viral and anti-inflammatory effects of kaempferol and quercetin and COVID-2019: a scoping review</article-title>. <source>Asian Pac. J. Trop. Biomed.</source> <volume>11</volume>:<fpage>327</fpage>. doi: <pub-id pub-id-type="doi">10.4103/2221-1691.319567</pub-id></citation></ref>
<ref id="ref32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kishu</surname> <given-names>T.</given-names></name> <name><surname>Siva</surname> <given-names>K.</given-names></name></person-group> (<year>2011</year>). <article-title>Cholic acid as a Lead molecule: a review</article-title>. <source>Asian J. Res. Chem.</source> <volume>4</volume>, <fpage>683</fpage>&#x2013;<lpage>684</lpage>. doi: <pub-id pub-id-type="doi">10.5958/0974-4150</pub-id></citation></ref>
<ref id="ref33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname> <given-names>S.</given-names></name> <name><surname>Prasad</surname> <given-names>A.</given-names></name> <name><surname>Iyer</surname> <given-names>S.</given-names></name> <name><surname>Vaidya</surname> <given-names>S.</given-names></name></person-group> (<year>2013</year>). <article-title>Systematic pharmacognostical, phytochemical and pharmacological review on an ethno medicinal plant, <italic>Basella alba</italic> L</article-title>. <source>J. Pharmacogn. Phytother.</source> <volume>5</volume>, <fpage>53</fpage>&#x2013;<lpage>58</lpage>. doi: <pub-id pub-id-type="doi">10.5897/JPP12.0256</pub-id></citation></ref>
<ref id="ref34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kumer</surname> <given-names>A.</given-names></name> <name><surname>Chakma</surname> <given-names>U.</given-names></name> <name><surname>Chandro</surname> <given-names>A.</given-names></name> <name><surname>Howlader</surname> <given-names>D.</given-names></name> <name><surname>Akash</surname> <given-names>S.</given-names></name> <name><surname>Kobir</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Modified D-glucofuranose computationally screening for inhibitor of breast cancer and triple breast cancer: chemical descriptor, molecular docking, molecular dynamics and QSAR</article-title>. <source>J. Chil. Chem. Soc.</source> <volume>67</volume>, <fpage>5623</fpage>&#x2013;<lpage>5635</lpage>. doi: <pub-id pub-id-type="doi">10.4067/S0717-97072022000305623</pub-id></citation></ref>
<ref id="ref35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kumer</surname> <given-names>A.</given-names></name> <name><surname>Chakma</surname> <given-names>U.</given-names></name> <name><surname>Matin</surname> <given-names>M. M.</given-names></name> <name><surname>Akash</surname> <given-names>S.</given-names></name> <name><surname>Chando</surname> <given-names>A.</given-names></name> <name><surname>Howlader</surname> <given-names>D.</given-names></name></person-group> (<year>2021</year>). <article-title>The computational screening of inhibitor for black fungus and white fungus by D-glucofuranose derivatives using in silico and SAR study</article-title>. <source>Organ. Commun.</source> <volume>14</volume>, <fpage>305</fpage>&#x2013;<lpage>322</lpage>. doi: <pub-id pub-id-type="doi">10.25135/acg.oc.116.2108.2188</pub-id></citation></ref>
<ref id="ref36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kumer</surname> <given-names>A.</given-names></name> <name><surname>Chakma</surname> <given-names>U.</given-names></name> <name><surname>Rana</surname> <given-names>M. M.</given-names></name> <name><surname>Chandro</surname> <given-names>A.</given-names></name> <name><surname>Akash</surname> <given-names>S.</given-names></name> <name><surname>Elseehy</surname> <given-names>M. M.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Investigation of the new inhibitors by sulfadiazine and modified derivatives of &#x03B1;-D-glucopyranoside for white spot syndrome virus disease of shrimp by in silico: quantum calculations, molecular docking, ADMET and molecular dynamics study</article-title>. <source>Molecules</source> <volume>27</volume>:<fpage>3694</fpage>. doi: <pub-id pub-id-type="doi">10.3390/molecules27123694</pub-id>, PMID: <pub-id pub-id-type="pmid">35744817</pub-id></citation></ref>
<ref id="ref37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kutluay</surname> <given-names>S. B.</given-names></name> <name><surname>Doroghazi</surname> <given-names>J.</given-names></name> <name><surname>Roemer</surname> <given-names>M. E.</given-names></name> <name><surname>Triezenberg</surname> <given-names>S. J. J. V.</given-names></name></person-group> (<year>2008</year>). <article-title>Curcumin inhibits herpes simplex virus immediate-early gene expression by a mechanism independent of p300/CBP histone acetyltransferase activity</article-title>. <source>Virology</source> <volume>373</volume>, <fpage>239</fpage>&#x2013;<lpage>247</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.virol.2007.11.028</pub-id></citation></ref>
<ref id="ref38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>Y.-Q.</given-names></name> <name><surname>Wang</surname> <given-names>S. F.</given-names></name></person-group> (<year>2006</year>). <article-title>Anti-hepatitis B activities of ganoderic acid from <italic>Ganoderma lucidum</italic></article-title>. <source>Biotechnol. Lett.</source> <volume>28</volume>, <fpage>837</fpage>&#x2013;<lpage>841</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10529-006-9007-9</pub-id></citation></ref>
<ref id="ref39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lindequist</surname> <given-names>U.</given-names></name> <name><surname>Niedermeyer</surname> <given-names>T. H.</given-names></name> <name><surname>J&#x00FC;lich</surname> <given-names>W.-D.</given-names></name></person-group> (<year>2005</year>). <article-title>The pharmacological potential of mushrooms</article-title>. <source>Evid. Based Complement. Alternat. Med.</source> <volume>2</volume>, <fpage>285</fpage>&#x2013;<lpage>299</lpage>. doi: <pub-id pub-id-type="doi">10.1093/ecam/neh107</pub-id></citation></ref>
<ref id="ref40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Naveed</surname> <given-names>M.</given-names></name> <name><surname>Hejazi</surname> <given-names>V.</given-names></name> <name><surname>Abbas</surname> <given-names>M.</given-names></name> <name><surname>Kamboh</surname> <given-names>A. A.</given-names></name> <name><surname>Khan</surname> <given-names>G. J.</given-names></name> <name><surname>Shumzaid</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2018</year>). <article-title>Chlorogenic acid (CGA): a pharmacological review and call for further research</article-title>. <source>Biomed. Pharmacother.</source> <volume>97</volume>, <fpage>67</fpage>&#x2013;<lpage>74</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.biopha.2017.10.064</pub-id></citation></ref>
<ref id="ref41"><citation citation-type="other"><person-group person-group-type="author"><collab id="coll2">New York Times</collab></person-group>. (<year>2022</year>). <italic>Explained: What to know about the West Nile virus in New York City</italic>. New York Times, New York City.</citation></ref>
<ref id="ref42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oo</surname> <given-names>A.</given-names></name> <name><surname>Hassandarvish</surname> <given-names>P.</given-names></name> <name><surname>Chin</surname> <given-names>S. P.</given-names></name> <name><surname>Lee</surname> <given-names>V. S.</given-names></name> <name><surname>Bakar</surname> <given-names>S. A.</given-names></name> <name><surname>Zandi</surname> <given-names>K. J. P.</given-names></name></person-group> (<year>2016</year>). <article-title>In silico study on anti-chikungunya virus activity of hesperetin</article-title>. <source>PeerJ</source> <volume>4</volume>:<fpage>e2602</fpage></citation></ref>
<ref id="ref43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Padmi</surname> <given-names>H.</given-names></name> <name><surname>Kharisma</surname> <given-names>D. V.</given-names></name> <name><surname>Ansori</surname> <given-names>A. N. M.</given-names></name> <name><surname>Sibero</surname> <given-names>M. T.</given-names></name> <name><surname>Widyananda</surname> <given-names>M. H.</given-names></name> <name><surname>Ullah</surname> <given-names>M.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Jurnal-macroalgae bioactive compounds for the potential antiviral of SARS-COV-2: an in silico study</article-title>. <source>J. Pure Appl. Microbiol.</source> <volume>16</volume>, <fpage>1018</fpage>&#x2013;<lpage>1027</lpage>. doi: <pub-id pub-id-type="doi">10.22207/JPAM.16.2.26</pub-id></citation></ref>
<ref id="ref44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname> <given-names>L.</given-names></name> <name><surname>Yang</surname> <given-names>S.</given-names></name> <name><surname>Cheng</surname> <given-names>Y. J.</given-names></name> <name><surname>Chen</surname> <given-names>F.</given-names></name> <name><surname>Pan</surname> <given-names>S.</given-names></name> <name><surname>Fan</surname> <given-names>G. J. F. S.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>Antifungal activity and action mode of pinocembrin from propolis against <italic>Penicillium italicum</italic></article-title>. <volume>21</volume>, <fpage>1533</fpage>&#x2013;<lpage>1539</lpage>.</citation></ref>
<ref id="ref45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Piret</surname> <given-names>J.</given-names></name> <name><surname>Boivin</surname> <given-names>G.</given-names></name></person-group> (<year>2021</year>). <article-title>Pandemics throughout history</article-title>. <source>Front. Microbiol.</source> <volume>11</volume>:<fpage>631736</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmicb.2020.631736</pub-id>, PMID: <pub-id pub-id-type="pmid">33584597</pub-id></citation></ref>
<ref id="ref46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rahman</surname> <given-names>M.</given-names></name> <name><surname>Islam</surname> <given-names>M.</given-names></name> <name><surname>Akash</surname> <given-names>S.</given-names></name> <name><surname>Mim</surname> <given-names>S.</given-names></name> <name><surname>Rahaman</surname> <given-names>M.</given-names></name> <name><surname>Bin Emran</surname> <given-names>T.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>In silico investigation and potential therapeutic approaches of natural products for COVID-19: computer-aided drug design perspective</article-title>. <source>Front. Cell. Infect. Microbiol.</source> <volume>12</volume>:<fpage>929430</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fcimb.2022.929430</pub-id></citation></ref>
<ref id="ref47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rahman</surname> <given-names>M. M.</given-names></name> <name><surname>Karim</surname> <given-names>M. R.</given-names></name> <name><surname>Ahsan</surname> <given-names>M. Q.</given-names></name> <name><surname>Khalipha</surname> <given-names>A. B. R.</given-names></name> <name><surname>Chowdhury</surname> <given-names>M. R.</given-names></name> <name><surname>Saifuzzaman</surname> <given-names>M.</given-names></name></person-group> (<year>2012</year>). <article-title>Use of computer in drug design and drug discovery: a review</article-title>. <source>Int. J. Pharmaceut. Life Sci.</source> <volume>1</volume>. doi: <pub-id pub-id-type="doi">10.3329/ijpls.v1i2.12955</pub-id></citation></ref>
<ref id="ref48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rahman</surname> <given-names>M. M.</given-names></name> <name><surname>Wang</surname> <given-names>X.</given-names></name> <name><surname>Islam</surname> <given-names>M. R.</given-names></name> <name><surname>Akash</surname> <given-names>S.</given-names></name> <name><surname>Supti</surname> <given-names>F. A.</given-names></name> <name><surname>Mitu</surname> <given-names>M. I.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Multifunctional role of natural products for the treatment of Parkinson&#x2019;s disease: at a glance</article-title>. <source>Front. Pharmacol.</source> <volume>13</volume>:<fpage>976385</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fphar.2022.976385</pub-id>, PMID: <pub-id pub-id-type="pmid">36299886</pub-id></citation></ref>
<ref id="ref49"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Raut</surname> <given-names>J. K.</given-names></name> <name><surname>Adhikari</surname> <given-names>M. K.</given-names></name></person-group>, <source>Mushroom: a true super food</source>. <publisher-loc>Khumaltar</publisher-loc>: <publisher-name>Nepal Academy of Science &#x0026; Technology</publisher-name>, (<year>2021</year>).</citation></ref>
<ref id="ref50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sadowski</surname> <given-names>J.</given-names></name> <name><surname>Kubinyi</surname> <given-names>H.</given-names></name></person-group> (<year>1998</year>). <article-title>A scoring scheme for discriminating between drugs and nondrugs</article-title>. <source>J. Med. Chem.</source> <volume>41</volume>, <fpage>3325</fpage>&#x2013;<lpage>3329</lpage>.</citation></ref>
<ref id="ref51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname> <given-names>G. B.</given-names></name> <name><surname>Ganesan</surname> <given-names>A.</given-names></name> <name><surname>Emery</surname> <given-names>F. S.</given-names></name></person-group> (<year>2016</year>). <article-title>Oral administration of peptide-based drugs: beyond Lipinski&#x2019;s rule</article-title>. <source>ChemMedChem</source> <volume>11</volume>, <fpage>2245</fpage>&#x2013;<lpage>2251</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cmdc.201600288</pub-id>, PMID: <pub-id pub-id-type="pmid">27596610</pub-id></citation></ref>
<ref id="ref52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schwarz</surname> <given-names>S.</given-names></name> <name><surname>Sauter</surname> <given-names>D.</given-names></name> <name><surname>Wang</surname> <given-names>K.</given-names></name> <name><surname>Zhang</surname> <given-names>R.</given-names></name> <name><surname>Sun</surname> <given-names>B.</given-names></name> <name><surname>Karioti</surname> <given-names>A.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Kaempferol derivatives as antiviral drugs against the 3a channel protein of coronavirus</article-title>. <source>Planta Med.</source> <volume>80</volume>, <fpage>177</fpage>&#x2013;<lpage>182</lpage>. doi: <pub-id pub-id-type="doi">10.1055/s-0033-1360277</pub-id></citation></ref>
<ref id="ref53"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Senthil Kumar</surname> <given-names>K.</given-names></name> <name><surname>Wang</surname> <given-names>S.-Y.</given-names></name></person-group>, &#x201C;<article-title>Pharmacological applications of lucidone: a naturally occurring cyclopentenedione</article-title>,&#x201D; in <source>Medicinal plants-recent advances in research and development</source>, <publisher-loc>Cham</publisher-loc> <publisher-name>Springer</publisher-name>, (<year>2016</year>), <fpage>273</fpage>&#x2013;<lpage>295</lpage>.</citation></ref>
<ref id="ref54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Song</surname> <given-names>N.-N.</given-names></name> <name><surname>Zhang</surname> <given-names>S.-Y.</given-names></name> <name><surname>Liu</surname> <given-names>C.-X.</given-names></name></person-group> (<year>2004</year>). <article-title>Overview of factors affecting oral drug absorption</article-title>. <source>Asian J. Drug Metab. Pharmacokinet.</source> <volume>4</volume>, <fpage>167</fpage>&#x2013;<lpage>176</lpage>.</citation></ref>
<ref id="ref55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sule</surname> <given-names>W. F.</given-names></name> <name><surname>Oluwayelu</surname> <given-names>D. O.</given-names></name> <name><surname>Hern&#x00E1;ndez-Triana</surname> <given-names>L. M.</given-names></name> <name><surname>Fooks</surname> <given-names>A. R.</given-names></name> <name><surname>Venter</surname> <given-names>M.</given-names></name> <name><surname>Johnson</surname> <given-names>N.</given-names></name></person-group> (<year>2018</year>). <article-title>Epidemiology and ecology of West Nile virus in sub-Saharan Africa</article-title>. <source>Parasit. Vectors</source> <volume>11</volume>, <fpage>1</fpage>&#x2013;<lpage>10</lpage>. doi: <pub-id pub-id-type="doi">10.1186/s13071-018-2998-y</pub-id></citation></ref>
<ref id="ref56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sunthamala</surname> <given-names>N.</given-names></name> <name><surname>Suebsamran</surname> <given-names>C.</given-names></name> <name><surname>Khruaphet</surname> <given-names>N.</given-names></name> <name><surname>Sankla</surname> <given-names>N.</given-names></name> <name><surname>Janpirom</surname> <given-names>J.</given-names></name> <name><surname>Khankhum</surname> <given-names>S.</given-names></name> <etal/></person-group>. (<year>2020</year>). <article-title>Sanguinarine and Chelidonine synergistically induce endosomal toll-like receptor and M1-associated mediators expression</article-title>. <source>J. Pure Appl. Microbiol.</source> <volume>14</volume>, <fpage>2351</fpage>&#x2013;<lpage>2361</lpage>. doi: <pub-id pub-id-type="doi">10.22207/JPAM.14.4.13</pub-id></citation></ref>
<ref id="ref57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Syng-Ai</surname> <given-names>C.</given-names></name> <name><surname>Kumari</surname> <given-names>A. L.</given-names></name> <name><surname>Khar</surname> <given-names>A.</given-names></name></person-group> (<year>2004</year>). <article-title>Effect of curcumin on normal and tumor cells: role of glutathione and bcl-2</article-title>. <source>Mol. Cancer Ther.</source> <volume>3</volume>, <fpage>1101</fpage>&#x2013;<lpage>1108</lpage>.</citation></ref>
<ref id="ref58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Terefe</surname> <given-names>E. M.</given-names></name> <name><surname>Ghosh</surname> <given-names>A.</given-names></name></person-group> (<year>2022</year>). <article-title>Molecular docking, validation, dynamics simulations, and pharmacokinetic prediction of phytochemicals isolated from <italic>Croton dichogamus</italic> against the HIV-1 reverse transcriptase</article-title>. <source>Bioinformat. Biol. Insights</source> <volume>16</volume>. doi: <pub-id pub-id-type="doi">10.1177/11779322221125605</pub-id></citation></ref>
<ref id="ref59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tilgner</surname> <given-names>M.</given-names></name> <name><surname>Shi</surname> <given-names>P.-Y.</given-names></name></person-group> (<year>2004</year>). <article-title>Structure and function of the 3&#x2032; terminal six nucleotides of the West Nile virus genome in viral replication</article-title>. <source>J. Virol.</source> <volume>78</volume>, <fpage>8159</fpage>&#x2013;<lpage>8171</lpage>. doi: <pub-id pub-id-type="doi">10.1128/JVI.78.15.8159-8171.2004</pub-id>, PMID: <pub-id pub-id-type="pmid">15254187</pub-id></citation></ref>
<ref id="ref60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wahyuni</surname> <given-names>D. K.</given-names></name> <name><surname>Wacharasindhu</surname> <given-names>S.</given-names></name> <name><surname>Bankeeree</surname> <given-names>W.</given-names></name> <name><surname>Punnapayak</surname> <given-names>H.</given-names></name> <name><surname>Parikesit</surname> <given-names>A.</given-names></name> <name><surname>Kharisma</surname> <given-names>V.</given-names></name></person-group> (<year>2022</year>). <article-title>Molecular simulation of compounds from n-hexane fraction of <italic>Sonchus arvensis</italic> L. leaves as SARS-CoV-2 antiviral through inhibitor activity targeting strategic viral protein</article-title>. <source>J. Pharm. Pharmacogn. Res.</source> <volume>10</volume>, <fpage>1126</fpage>&#x2013;<lpage>1138</lpage>. doi: <pub-id pub-id-type="doi">10.56499/jppres22.1489_10.6.1126</pub-id></citation></ref>
<ref id="ref61"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Walters</surname> <given-names>W. P.</given-names></name></person-group> (<year>2012</year>). <article-title>Going further than Lipinski&#x2019;s rule in drug design</article-title>. <source>Expert Opin. Drug Discovery</source> <volume>7</volume>, <fpage>99</fpage>&#x2013;<lpage>107</lpage>. doi: <pub-id pub-id-type="doi">10.1517/17460441.2012.648612</pub-id>, PMID: <pub-id pub-id-type="pmid">22468912</pub-id></citation></ref>
<ref id="ref62"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>E.</given-names></name> <name><surname>Sun</surname> <given-names>H.</given-names></name> <name><surname>Wang</surname> <given-names>J.</given-names></name> <name><surname>Wang</surname> <given-names>Z.</given-names></name> <name><surname>Liu</surname> <given-names>H.</given-names></name> <name><surname>Zhang</surname> <given-names>J. Z.</given-names></name> <etal/></person-group>. (<year>2019</year>). <article-title>End-point binding free energy calculation with MM/PBSA and MM/GBSA: strategies and applications in drug design</article-title>. <source>Chem. Rev.</source> <volume>119</volume>, <fpage>9478</fpage>&#x2013;<lpage>9508</lpage>. doi: <pub-id pub-id-type="doi">10.1021/acs.chemrev.9b00055</pub-id>, PMID: <pub-id pub-id-type="pmid">31244000</pub-id></citation></ref>
<ref id="ref63"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wijaya</surname> <given-names>R. M.</given-names></name> <name><surname>Hafidzhah</surname> <given-names>M. A.</given-names></name> <name><surname>Kharisma</surname> <given-names>V. D.</given-names></name> <name><surname>Ansori</surname> <given-names>A. N. M.</given-names></name> <name><surname>Parikesit</surname> <given-names>A. A.</given-names></name></person-group> (<year>2021</year>). <article-title>COVID-19 in silico drug with <italic>Zingiber officinale</italic> natural product compound library targeting the Mpro protein</article-title>. <source>Makara J. Sci.</source> <volume>25</volume>:<fpage>5</fpage>. doi: <pub-id pub-id-type="doi">10.7454/mss.v25i3.1244</pub-id></citation></ref>
<ref id="ref64"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname> <given-names>X.</given-names></name> <name><surname>Qi</surname> <given-names>M.</given-names></name> <name><surname>Li</surname> <given-names>P.</given-names></name> <name><surname>Zhan</surname> <given-names>Y.</given-names></name> <name><surname>Shao</surname> <given-names>H. J. C.</given-names></name></person-group> (<year>2017</year>). <article-title>Apigenin in cancer therapy: anti-cancer effects and mechanisms of action</article-title>. <source>Cell Biosci.</source> <volume>7</volume>, <fpage>1</fpage>&#x2013;<lpage>16</lpage>.</citation></ref>
<ref id="ref65"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname> <given-names>S.</given-names></name> <name><surname>Chan</surname> <given-names>H. S.</given-names></name> <name><surname>Hu</surname> <given-names>Z.</given-names></name></person-group> (<year>2017</year>). <article-title>Using PyMOL as a platform for computational drug design</article-title>. <source>Wiley Interdiscip. Rev. Comput. Mol. Sci.</source> <volume>7</volume>:<fpage>e1298</fpage>. doi: <pub-id pub-id-type="doi">10.1002/wcms.1298</pub-id></citation></ref>
<ref id="ref66"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname> <given-names>X.</given-names></name> <name><surname>Luo</surname> <given-names>K.</given-names></name> <name><surname>Zhang</surname> <given-names>K.</given-names></name> <name><surname>He</surname> <given-names>J.</given-names></name> <name><surname>Zhao</surname> <given-names>Y.</given-names></name> <name><surname>Yu</surname> <given-names>D.</given-names></name></person-group> (<year>2016</year>). <article-title>Combinatorial vibration-mode assignment for the FTIR spectrum of crystalline melamine: a strategic approach toward theoretical IR vibrational calculations of triazine-based compounds</article-title>. <source>J. Phys. Chem. A</source> <volume>120</volume>, <fpage>7427</fpage>&#x2013;<lpage>7433</lpage>. doi: <pub-id pub-id-type="doi">10.1021/acs.jpca.6b06015</pub-id></citation></ref>
<ref id="ref67"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yuliana</surname> <given-names>D.</given-names></name> <name><surname>Bahtiar</surname> <given-names>F. I.</given-names></name> <name><surname>Najib</surname> <given-names>A.</given-names></name></person-group> (<year>2013</year>). <article-title>In silico screening of chemical compounds from roselle (<italic>Hibiscus Sabdariffa</italic>) as angiotensin-I converting enzyme inhibitor used PyRx program</article-title>. <source>ARPN J. Sci. Technol.</source> <volume>3</volume>, <fpage>1158</fpage>&#x2013;<lpage>1160</lpage>.</citation></ref>
<ref id="ref68"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zandi</surname> <given-names>K.</given-names></name> <name><surname>Ramedani</surname> <given-names>E.</given-names></name> <name><surname>Mohammadi</surname> <given-names>K.</given-names></name> <name><surname>Tajbakhsh</surname> <given-names>S.</given-names></name> <name><surname>Deilami</surname> <given-names>I.</given-names></name> <name><surname>Rastian</surname> <given-names>Z.</given-names></name> <etal/></person-group>. (<year>2010</year>). <article-title>Evaluation of antiviral activities of curcumin derivatives against HSV-1 in Vero cell line</article-title>. <source>Nat. Prod. Commun.</source> <volume>5</volume>, <fpage>1935</fpage>&#x2013;<lpage>19388</lpage>. doi: <pub-id pub-id-type="doi">10.1177/1934578X1000501220</pub-id></citation></ref>
<ref id="ref69"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zandi</surname> <given-names>K.</given-names></name> <name><surname>Teoh</surname> <given-names>B.-T.</given-names></name> <name><surname>Sam</surname> <given-names>S.-S.</given-names></name> <name><surname>Wong</surname> <given-names>P.-F.</given-names></name> <name><surname>Mustafa</surname> <given-names>M. R.</given-names></name> <name><surname>AbuBakar</surname> <given-names>S.</given-names></name></person-group> (<year>2011</year>). <article-title>Antiviral activity of four types of bioflavonoid against dengue virus type-2</article-title>. <source>Virol. J.</source> <volume>8</volume>, <fpage>1</fpage>&#x2013;<lpage>11</lpage>. doi: <pub-id pub-id-type="doi">10.1186/1743-422X-8-560</pub-id></citation></ref>
<ref id="ref70"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>W.</given-names></name> <name><surname>Qiao</surname> <given-names>H.</given-names></name> <name><surname>Lv</surname> <given-names>Y.</given-names></name> <name><surname>Wang</surname> <given-names>J.</given-names></name> <name><surname>Chen</surname> <given-names>X.</given-names></name> <name><surname>Hou</surname> <given-names>Y.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Apigenin inhibits enterovirus-71 infection by disrupting viral RNA association with trans-acting factors</article-title>. <source>PLoS One</source> <volume>9</volume>:<fpage>e110429</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0110429</pub-id></citation></ref>
<ref id="ref71"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>W.</given-names></name> <name><surname>Tao</surname> <given-names>J.</given-names></name> <name><surname>Yang</surname> <given-names>X.</given-names></name> <name><surname>Yang</surname> <given-names>Z.</given-names></name> <name><surname>Zhang</surname> <given-names>L.</given-names></name> <name><surname>Liu</surname> <given-names>H.</given-names></name> <etal/></person-group>. (<year>2014</year>). <article-title>Antiviral effects of two <italic>Ganoderma lucidum</italic> triterpenoids against enterovirus 71 infection</article-title>. <source>Biochem. Biophys. Res. Commun.</source> <volume>449</volume>, <fpage>307</fpage>&#x2013;<lpage>312</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.bbrc.2014.05.019</pub-id></citation></ref>
<ref id="ref72"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>T.</given-names></name> <name><surname>Wu</surname> <given-names>Z.</given-names></name> <name><surname>Du</surname> <given-names>J.</given-names></name> <name><surname>Hu</surname> <given-names>Y.</given-names></name> <name><surname>Liu</surname> <given-names>L.</given-names></name> <name><surname>Yang</surname> <given-names>F.</given-names></name> <etal/></person-group>. (<year>2012</year>). <article-title>Anti-Japanese-encephalitis-viral effects of kaempferol and daidzin and their RNA-binding characteristics</article-title>. <source>PLoS One</source> <volume>7</volume>:<fpage>e30259</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0030259</pub-id></citation></ref>
<ref id="ref73"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>X.</given-names></name> <name><surname>Cui</surname> <given-names>Q.</given-names></name> <name><surname>Fu</surname> <given-names>Q.</given-names></name> <name><surname>Song</surname> <given-names>X.</given-names></name> <name><surname>Jia</surname> <given-names>R.</given-names></name> <name><surname>Yang</surname> <given-names>Y.</given-names></name> <etal/></person-group>. (<year>2017</year>). <article-title>Antiviral properties of resveratrol against pseudorabies virus are associated with the inhibition of I&#x03BA;B kinase activation</article-title>. <source>Sci. Rep.</source> <volume>7</volume>, <fpage>1</fpage>&#x2013;<lpage>11</lpage>.</citation></ref>
<ref id="ref74"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>Y.</given-names></name> <name><surname>Ray</surname> <given-names>D.</given-names></name> <name><surname>Zhao</surname> <given-names>Y.</given-names></name> <name><surname>Dong</surname> <given-names>H.</given-names></name> <name><surname>Ren</surname> <given-names>S.</given-names></name> <name><surname>Li</surname> <given-names>Z.</given-names></name> <etal/></person-group>. (<year>2007</year>). <article-title>Structure and function of flavivirus NS5 methyltransferase</article-title>. <source>J. Virol.</source> <volume>81</volume>, <fpage>3891</fpage>&#x2013;<lpage>3903</lpage>. doi: <pub-id pub-id-type="doi">10.1128/JVI.02704-06</pub-id>, PMID: <pub-id pub-id-type="pmid">17267492</pub-id></citation></ref>
<ref id="ref75"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname> <given-names>Y.</given-names></name> <name><surname>Yu</surname> <given-names>Y.</given-names></name> <name><surname>Lv</surname> <given-names>H.</given-names></name> <name><surname>Zhang</surname> <given-names>H.</given-names></name> <name><surname>Liang</surname> <given-names>T.</given-names></name> <name><surname>Zhou</surname> <given-names>G.</given-names></name> <etal/></person-group>. (<year>2022</year>). <article-title>Apigenin in cancer therapy: from mechanism of action to nano-therapeutic agent</article-title>. <source>Food Chem. Toxicol.</source> <volume>168</volume>:<fpage>113385</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.fct.2022.113385</pub-id></citation></ref>
<ref id="ref76"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>J.</given-names></name> <name><surname>Song</surname> <given-names>S.</given-names></name> <name><surname>Sun</surname> <given-names>Z.</given-names></name> <name><surname>Lian</surname> <given-names>L.</given-names></name> <name><surname>Shi</surname> <given-names>L.</given-names></name> <name><surname>Ren</surname> <given-names>A.</given-names></name> <etal/></person-group>. (<year>2021</year>). <article-title>Regulation of glutamine synthetase activity by transcriptional and posttranslational modifications negatively influences ganoderic acid biosynthesis in <italic>Ganoderma lucidum</italic></article-title>. <source>Environ. Microbiol.</source> <volume>23</volume>, <fpage>1286</fpage>&#x2013;<lpage>1297</lpage>. doi: <pub-id pub-id-type="doi">10.1111/1462-2920.15400</pub-id></citation></ref>
<ref id="ref77"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zikri</surname> <given-names>A. T.</given-names></name> <name><surname>Pranowo</surname> <given-names>H. D.</given-names></name> <name><surname>Haryadi</surname> <given-names>W.</given-names></name></person-group> (<year>2020</year>). <article-title>Stability, hydrogen bond occupancy analysis and binding free energy calculation from flavonol docked in DAPK1 active site using molecular dynamic simulation approaches</article-title>. <source>Indon. J. Chem.</source> <volume>21</volume>, <fpage>383</fpage>&#x2013;<lpage>390</lpage>. doi: <pub-id pub-id-type="doi">10.22146/ijc.56087</pub-id></citation></ref>
<ref id="ref78"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Zuo</surname> <given-names>J.</given-names></name> <name><surname>Tang</surname> <given-names>W.</given-names></name> <name><surname>Xu</surname> <given-names>Y.</given-names></name></person-group> (<year>2015</year>). &#x201C;<article-title>Anti-hepatitis B virus activity of chlorogenic acid and its related compounds</article-title>&#x201D; in <source>Coffee in health and disease prevention</source> (<publisher-loc>Amsterdam</publisher-loc>: <publisher-name>Elsevier</publisher-name>), <fpage>607</fpage>&#x2013;<lpage>613</lpage>.</citation></ref>
</ref-list>
<fn-group>
<fn id="fn0004"><p><sup>1</sup><ext-link xlink:href="http://www.swissadme.ch/index.php" ext-link-type="uri">http://www.swissadme.ch/index.php</ext-link></p></fn>
<fn id="fn0005"><p><sup>2</sup><ext-link xlink:href="https://biosig.lab.uq.edu.au/pkcsm/prediction" ext-link-type="uri">https://biosig.lab.uq.edu.au/pkcsm/prediction</ext-link></p></fn>
<fn id="fn0006"><p><sup>3</sup><ext-link xlink:href="https://pymol.org/2/" ext-link-type="uri">https://pymol.org/2/</ext-link></p></fn>
</fn-group>
</back>
</article>
